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ABSTRACT

Author: Lavan, Monika. PhD
Institution: Purdue University
Degree Received: August 2018
Title: Formulation Strategies and Optimization of Poorly Water-Soluble Drugs for Preclinical
and Clinical Applications
Committee Chair: Gregory Knipp
Successful mitigation of a disease or clinical condition requires efficacious and safe drug
compounds that are designed to provide the right balance of properties including potency,
specificity, safety, solubility, absorption and metabolic stability. In general, performance is
governed by the physicochemical properties of the drug, the composition and properties of the
dosage form, and their ability to provide release in a manner that overcomes the physiological
barriers limiting exposure at the site of action. That being said, it is often very challenging to obtain
a new therapeutic compound that possesses an optimal balance of these properties because of the
broad chemical space in which the drug candidates can possess and the significant variability in
physiology that can change both intra- and inter-individually during dosing. For example, an
increase in potency that is achieved through elevated lipophilicity of a compound can lead to poor
water solubility, which may require a solubility enhancing formulation to achieve the desired
therapeutic levels in a patient. In fact, there has been an evolving trend in the drug discovery
process to improve potency of the molecules by adding lipophilic moieties needed to demonstrate
efficacy in cell-based assays, and even animal models, termed molecular obesity1–4. It has been
noted that this has resulted in a significant increase of the generation of highly insoluble drug
candidates. However, the perceived therapeutic benefit associated with high in vitro potency may
be lost due to poor absorption, distribution, metabolism, excretion and toxicity (ADMET)
properties.
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To overcome the challenges associated with poorly soluble drugs, the pharmaceutical
industry initiated the interface of drug discovery and development. It encourages early
optimization to take place as a combined effort between those two stages. Solubility-enabling
formulation strategies are utilized to develop drug-like compounds that can survive through
different stages of drug development and ultimately become marketed products. An alignment
between drug discovery and development therefore becomes essential and requires advanced
knowledge in the selection of the appropriate compounds and formulation science.
Chapter 1 provides a discussion on the potential effects of commonly-used solubilizing
excipients on the activities of drug transporters. The excipients at clinically-safe levels have long
been thought to be inert, but many studies have led to an enhanced understanding of how many
solubilizing excipients may modulate drug transporters and enzymes resulting in unexpected
pharmacological effects. The relevance with respect to this chapter is the potential for these
excipients to interact with a physiological barrier and modulate the functions of drug transporters
and enzymes. The goal here is to review the literature in this area and provide some insights into
whether these effects arise from direct interactions or as a consequence of indirect effects like
solubility enhancement influencing saturation of these isoforms as predicted by Michaelis-Menten
kinetics. As the continued use of these excipients is being closely monitored by the regulatory
agency, the difference between direct physiological activities or indirect effects like solubility
enhancement is warranted. Current literature does not always delineate the mechanisms of
permeability enhancement, hence creating a significant knowledge gap in our current
understanding. Consequently, there may be unwanted scrutiny placed on excipient classes due to
perceived pharmacological activity which may or may not exist.

xiv
Chapter 2 discusses the addition of dendrimer-like biopolymers (DLB) as the polymeric
matrix to stabilize the amorphous dispersion formulation of strong crystallizing compounds
(niclosamide, celecoxib and resveratrol). The crystallization inhibition and effect of DLB’s on
apparent permeability of drug across Caco-2 cell monolayers are evaluated and compared to the
results obtained from using commercially available polymers. The interplay between
concentration (i.e. apparent solubility) and permeability is demonstrated, and physiological
considerations are discussed.
Chapter 3 is an introduction to pediatric drug development, and it presents the current
progress made to achieve better medicines for children. The lack of pediatric drug formulation and
patient-centric products has led to off-label use of adult medicines, which can affect the drug
performance and causes serious side effects. Pediatric population consists of multiple subgroups
including neonates, infants, children and adolescents. The changes in anatomical properties, organ
capacity, drug transporter activities and enzymatic expression can alter clinical outcomes in
pediatric populations. The ontogeny-related effects need to be investigated and their impact on
clinical pharmacology need to be incorporated in preclinical and clinical studies. In addition,
innovative solid dosage form with dose flexibility and improved patient adherence can be used to
overcome challenges in drug administration to children. The effects of body development on drug
ADMET properties play an important role in pediatric drug product development.
Finally, a platform created to expedite preclinical testing in pediatric drug development is
presented in Chapter 4. Multiple considerations were incorporated to address the main challenges
in dose flexibility and patient adherence. Mini-tablets, 2 mm in diameter, were manufactured using
rotary tablet press at a set weight and compression force level. The physical characteristics were
consistent for mini-tablets throughout multiple batches. Polymeric amorphous solid dispersion

xv
(ASD) was used as a solubility enhancing technique to increase solubility and exposure of lapatinib.
The effects of polymeric excipient and disintegrant on drug release properties were investigated.
While having a lower apparent solubility and shorter storage stability, hydroxypropyl
methylcellose E3 (HPMCE3) formulation provided a higher percentage of drug release compared
to hydroxypropyl methylcellulose phthalate (HPMCP). The intermolecular interaction within the
ASD system plays a role in the level of apparent solubility, physical stability and concentration of
free drug available in an aqueous environment. Juvenile porcine models at two different weight
groups (10 and 20 kg) were used to obtain the pharmacokinetic parameters of lapatinib. While the
dose-normalized exposure of drug was found to be lower in the pig study, the dose flexibility of
mini-tablets enabled a constant dose level to be administered to achieve equivalent plasma
concentration-time profiles between the two groups. This linear scaling in the amount of drug in
pediatric and adult population has also been observed in human clinical studies.
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FUNCTIONAL EFFECTS OF SOLUBILIZING
EXCIPIENTS ON DRUG TRANSPORTERS AND ABSORPTION

Modified from: Lavan M, Knipp GT.
Functional Effects of Solubilizing Excipients on Drug Transporters and Absorption.
(In Preparation)

1.1

Introduction
Excipients such as surfactants and emulsifying polymers are commonly used as solubilizing

agents in pharmaceutical formulations to address challenges associated with the development of
poorly soluble drugs1. Solubility enhancing excipients often enable preclinical in vitro cell culture
assay and in vivo animal pharmacokinetic studies to be conducted at targeted doses and efficacious
levels in the absence of potentially harmful cosolvents2,3. Surfactant molecules undergo selfassociation in aqueous solution to form micelles, which consist of a hydrophobic core capable of
forming drug complexes through van der Waal (interior core) and a polar (surface) interactions
with water that allows apparent solubilization to occur. Such micelle formations occur at or above
the critical micelle concentration (CMC) for the surfactant monomer based on the amphiphilic
nature of the surfactant as well as other conditions within the solution system4. The interaction
between emulsifying excipients and hydrophobic drug molecules makes them appropriate for
stability control and absorption enhancement due to the increased micellar drug solubility.
Moreover, the robustness in chemical synthesis of surfactants and polymeric compounds enable
scientists to rationally design numerous excipients having favorable interactions with drug
molecules and solubilizing interactions with water. As a result, there has been a drastic increase in
the number of excipients available as solubility enhancers in recent years5. However, in the absence
of potential micellar transport systems or membrane interactions, the absorption of the free drug
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is rate determining for bioavailability. Micellar uptake has been implicated in lymphatic delivery
as well, so it is not clear if all of the drug absorbed will appear in the systemic circulation6–9.
Although surfactants are included in formulations to achieve wetting effect, micellar
solubilization and increased drug solubility, many studies suggest that they also exhibit unintended
pharmacological effects leading to changes in the drug absorption10. For example, surfactants and
polymers reportedly may alter the peroral absorption of many therapeutic agents by modulating
the functions of transporters and enzymes present in the gastrointestinal tract11,12. Transporters and
enzymes play a major role in absorption, disposition and bioavailability of the drug in the body
and at the site of action. Their presence in the enterocytes and hepatocytes, for instance, helps
govern the amount of drug entering systemic circulation and directly participate in first pass
metabolism13.
There are two superfamilies of drug transporters, namely the ATP-binding cassette (ABC)
and solute carrier (SLC). ABC transporters directly depend on ATP as the energy source for their
function, whereas members of the SLC superfamily use either a chemical gradient (facilitative) or
energy sources (active) to mediate the transport of substrates across the plasma membrane14,15.
Based on the direction in which the substrate is carried across the cell barrier, transporters can be
categorized as uptake or efflux transporters. There are approximately 50 ABC transporter members,
whereas over 300 SLC transporters have been identified15. Current characterization of these
members related to drug transporting activity has been limited to a relatively low number of
transporters in each family. The International Transporter Consortium has held several workshops
and published several seminal reviews and made recommendations regarding the primary drug
transporter isoforms of clinical interest16–20. Predictions on the potential impact of genetic
polymorphisms and their impact on Absorption, Distribution, Metabolism and Excretion has also
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been recently reviewed by the ITC, and recommendations have been put forth to help focus
preclinical and clinical research in the field 21,22.
P-glycoprotein (ABCB1, P-gp) is one of the most studied efflux transporters responsible for
the transport of drugs and xenobiotic compounds from the cytoplasm through the apical membrane
of the intestinal barrier23. Other examples of efflux transporters are breast cancer resistance
proteins (BCRP, ABCG2), multidrug resistance proteins (MRP2, ABCC2) and bile salt export
pumps (BSEP, ABCB11)24–27. In contrast, multidrug resistance isoforms (e.g., MRP1 [ABCC1]
and MRP3 [ABCC3]) that are localized on the basolateral membrane of intestinal epithelium can
efflux drugs back into the body and limit their secretion into the intestinal lumen 15. It should be
noted that in many cases, the results arise from in vitro permeability studies where the ratio of the
Basolateral (hepatic blood flow) to Apical (intestinal lumen) permeability rate divided by the
permeability rate from the Apical to Basolateral side. It is assumed that ratios greater that 2-3x
are considered to indicate multidrug efflux arising from ABC transporters. As concentrations of
the drug are increased, it is common to see these ratios approach one without solubility
enhancement28,29. It is interesting to note that several reports suggest that the excipient effects more
than one ABC transporter implicated in multidrug resistant efflux that can complicate the
delineation of rate determining transporter effects in vivo29,30. In a more recent publication, a
database has been established to investigate the potential pharmacological effects of excipients on
transporters and/or enzymes through an in silico modeling approach.
Due to their reported inhibitory effects on efflux transporters, some surfactants and
emulsifying polymers have been introduced as oral absorption enhancers with the justification
derived from reports in overcoming multiple drug resistance (MDR) in cancer treatment31.
However, a concern may arise if the excipients influence the activities of influx drug transporters
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and result in a decreased mucosal-to-serosal permeability lowering drug absorption. In addition to
transporter inhibition, solubilizing excipients can also alter drug bioavailability by modulating
metabolic enzymes such as cytochrome P450 (CYP), UDP-glucuronosyltransferase (UGT) and
esterase, which are responsible for metabolism of 75% of drug in the market32,33. The drugmetabolizing enzyme cytochrome P450 3A polypeptide 4 (CYP3A4) was discovered in the liver
and intestinal cells - both of which are known to contribute to first-pass metabolism34. Drug
metabolism is divided into three phases. Phase I is the oxidation, reduction and hydrolysis stage
and phase II is the conjugation phase. The drug metabolism episode in phase III involves
transporters as they play an essential role in renal and biliary clearance35. Excipient-induced
changes in enzymatic activities can potentially alter bioavailability and introduce unwanted drugxenobiotic interactions36. Proper functional modes of drug metabolizing enzymes are essential for
safe and efficacious therapeutic outcomes37.
Representative SLC superfamily active transporter members include the proton dependent
oligopeptide transporters (e.g., PepT1, SLC15A1), organic anion transporting polypeptides (e.g.,
OATP1B1, SLO1B1), organic cation transporters (OCT1, SLC22A1), monocarboxylic acid
transporters (e.g., MCT1, SLC16A1), and apical sodium dependent bile acid transporters (ASBT,
SLC10A2) and are expressed in intestinal enterocytes38–41. These active transporters rely on
secondary ion gradients to drive the transport of their solutes into cells including the absorptive
enterocytes lining the gastrointestinal epithelium. Their presence is particularly implicated in
nutrient absorption, but many therapeutic agents are also SLC isoform substrates. However,
research specifically delineating the mechanisms by which excipients may affect these transporter
isoforms are still not well understood. Furthermore, drug transporter and metabolism also needs
to be to be carefully delineated42,43. The reported effects of these excipients on the activities of
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drug transporters and metabolic enzymes may also lead to inaccurate interpretations of
experimental data as well as toxicity-related issues in patients. Moreover, processing induced
variation in excipient concentrations during the dosage form scale up from benchtop to pilot to
large clinical manufacturing scales may actually influence oral drug absorption and impact clinical
findings. Therefore, further knowledge and understanding of excipient behaviors and their
potential effects on the transporters and enzymes present in both in vitro and in vivo models are of
critical importance for drug development processes from translation to post-marketing surveillance.
Critical excipient concentrations that improve bioavailability may need to be fixed in the quality
target product profile with the drug concentration, making it essential to identify with validated
Process Analytical Technologies and a key parameter within the Quality by Design space.
Given the current attention and the numerous reports of potential excipient effects on drug
transporters and enzymes, it is essential that we carefully discuss the criteria for establishing a
direct effect of an excipient on a transporter. Many of the excipients may have other effects, e.g.
solubilization, that may lead to saturation dependent transporter or enzyme kinetics that may be
construed as an excipient-isoform interaction. Care must be given to confounding variables when
claiming such an interaction is occurring. Here we will review some of the current literature
surrounding the reported excipient effects on drug transporters and enzymes and offer potential
considerations that need to be considered during characterization.

1.2

Surfactant-Mediated Changes in The Activities of Drug Transporters
Excipients have been widely reports to modulate activities of drug transporters throughout

the GI tract where drug absorption normally takes place after oral administration. Both uptake and
efflux transporters can be functionally affected by commonly used excipients for solubility
enhancement in oral drug formulations11,44. Surfactants are divided into ionic and nonionic
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categories. Polyethoxylated surfactant is a major group of nonionic solubilizing excipients
commonly selected due to its higher hydrophobic content compared to ionic surfactants. This
generally allows them to have greater solubilizing capacity and less damaging effect on the
biological membranes45. Some examples of polyethoxylated excipients include d-α-tocopheryl
polyethylene glycol succinates (TPGS), polysorbates (e.g., Tween 20 and 80), polyethylene glycol
ethers such as Cremophor EL, Cremophor RH40, Solutol HS15 etc., and poloxamers (Pluronic
block copolymers), all of which were found to be capable of modulating drug permeabilities due
to a perceived unidentified pharmacological response.
Table 1.1. Properties of commonly-used solubilizing excipients.
Example

TPGS 1000

Polysorbate 80

Cremophor EL

Pluronic P85

MW (Da)

1513

1310

2560

4600

0.02 wt%

0.0013 wt%

0.02 wt%

0.03 wt%

132 µM

10 µM

78 µM

67 µM

13

15

12 – 14

12 - 18

CMC
HLB

1.2.1 Polyethylene Glycols
Polyethylene glycol (PEG) is widely used in pharmaceutical research and development due
to its tunable properties and relatively low toxicity46. PEG 300 and PEG 400 have been
demonstrated to exhibit inhibitory effects on efflux transport of various drugs previously identified
as P-gp substrates including paclitaxel, doxorubicin, digoxin and rhodamine 12347–49. PEG 300
was shown to inhibit secretion of paclitaxel mediated by P-gp and/or other MRP efflux transporters
located on the apical side of Caco-2 cell monolayers in a concentration-dependent manner47. The
efflux ratio of Basolateral→Apical (BL→AP) to Apical→Basolateral (AP→BL) decreased from
41.9 in the sample without excipient to 1.16 when 20% v/v of PEG 300 was added. It was not clear
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if the 20% v/v concentration of PEG 300 was fixed only in the donor compartment or in both the
donor and receiver compartments in this study.
In a separate study by, Johnson et al48. PEG 400 was reported to increasingly inhibit digoxin
efflux as the excipient concentration was raised from as low as 1% to 20% w/v in a diffusion
chamber system mounted with rat jejunal tissue. This is consistent with results from another
experiment conducted by Shen et al., which used a diffusion chamber to investigate efflux changes
of rhodamine 123 in the presence of PEG with different molecular weights (200, 400 and 20,000
Da)49. The results indicated that efflux transport of rhodamine 123 was blocked in the presence of
all the PEG analogs tested regardless of their molecular weights. Shen et al. also utilized an in situ
closed loop method in a subsequent experiment which showed that increasing the concentration of
PEG 400 (0 to 5%) led to greater AUC values in plasma concentration versus time profile
accompanied by higher Cmax and decreases in Tmax and %bioavailability. It is important to note
that the inhibitory effects on efflux transporters were also observed amongst other PEG derivatives
such as PEG monolaurate, PEG monooleate and PEG monostearate.
1.2.2 D- α-Tocopheryl Poly(Ethylene Glycol) Succinates
D-α-tocopheryl poly(ethylene glycol) succinate (TPGS) is a group of synthetic excipients
composed of lipophilic α-tocopherol (vitamin E) and hydrophilic polyethylene glycol chain of
various lengths. TPGS 1000 is an FDA-approved excipient to be used as drug solubilizing agent
and an emulsifier50. As an amphiphilic compound, TPGS has also been used as a drug vehicle in
lipid-based drug delivery systems51. Collnot and coworkers utilized a rhodamine 123 transport
assay to demonstrate the effect of TPGS with different PEG chain lengths on inhibition of P-gp in
Caco-2 cell monolayers52. They found that TPGS induced polarity in the transport of rhodamine
123 by decreasing its BL→AP secretion and increasing its AP→BL absorption. This bi-directional
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change occurred at different levels based on the chain length of PEG polymer conjugated to TPGS
derivative tested. The most potent P-gp modulator was TPGS 1000. The inhibitory effect gradually
leveled off for chain lengths shorter or longer than that of PEG 1000. However, a separate Caco2 study conducted by Rege and colleagues observed that a decrease only occurred in the BL→AP
permeability of rhodamine 123 when TPGS 1000 (0.025 to 0.75 µM) was added53. The effect of
TPGS on drug absorption was also demonstrated in experiments using ex vivo and in vivo models.
Addition of TPGS 1000 at 0.5% w/v led to higher uptake of digoxin in an everted gut sacs
experiment and enhanced absorption of celiprolol in a pharmacokinetic study of rats54. Talinolol
is another beta blocker that is also a substrate for at least the apical efflux pump P-gp. When
talinolol was combined with 0.04% w/v of TPGS 1000 and administered to human volunteers
intubated with the 1-lumen naso-gastrointestinal tube, the extrapolated infinity AUC and Cmax
increased by 39% and 100% respectively55.
1.2.3 Polysorbates
Polysorbate refers to a group of nonionic surfactants derived from polyethoxylated sorbitan
and fatty acids. Results from several experiments revealed that polysorbate 20 (polyoxyethylene
sorbitan monolaurate) and polysorbate 80 (polyoxyethylene sorbitan monooleate) also modulated
the transport of drugs mediated by efflux pumps47,53–56. At a concentration of 0.05% w/v,
polysorbate 80 reduced the efflux ratio of paclitaxel from 13.2 in control to 5.32 after incorporation
of the excipient in an assay using Caco-2 cell monolayers56. Furthermore, Rege et al. determined
that the addition of polysorbate 80 (Tween 80) at concentration of 0.01 to 1 µM caused the efflux
ratio of rhodamine 123 to subside as a result of decreasing BL→AP and increasing AP→BL
permeability53. Bogman et al reported that polysorbate 80 has an IC50 values of 0.02% w/v based
on efflux assay using rhodamine 123 as the substrate in murine P388 cells over expressing P-gp57.
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Similarly, a tissue-based model using a diffusion chamber system demonstrated that the flux value
for basolateral to luminal transport of rhodamine 123 across rat intestinal membranes was
significantly reduced (from 0.680 to 0.456 pmol/min/cm2, p<0.05) when 0.1% w/v polysorbate 80
was added to the donor side (Shono et al.)58. However, Cornaire et al. utilized the everted gut sac
method and did not observe a significant increase in digoxin transport into the luminal bathing
media after co-administration of polysorbate 20 and polysorbate 80 at concentration ranges
between 0.05 and 0.5% w/v54. Changes in pharmacokinetic profiles in rats were observed with a
30% and 163% increase in AUC (0 to 10 hours) and Cmax, respectively, when 1% of Polysorbate
80 was added in a formulation containing digoxin as P-gp substrate59.
1.2.4 Cremophor EL
Cremophor EL is a polyethoxylated castor oil that consists of glycerol polyethylene glycol
ricinoleate and glycerol ethoxylate as the main components. It is synthesized by reacting hydroxyl
groups of castor oil triglyceride with ethylene oxides. Samples treated with Cremophor EL elicited
a significant decrease in the efflux ratio for substrates of P-gp including paclitaxel and rhodamine
123 when drug transport experiments were conducted across Caco-2 cell monolayers53,56. Cornaire
et al. observed a 2.9 fold increase in uptake of digoxin during a 90-minute time interval in everted
gut sac experiment when 0.5% w/v of Cremophor EL was added54. In addition, Shono and
coworkers established an in vitro diffusion chamber system and demonstrated that the introduction
of 0.01 to 0.1% w/v of Cremophor EL led to reduced efflux ratio of rhodamine 123 which is highly
active in the jejunal region of rat intestine58. Michaelis-Menten and Eadie-Hofstee plots
constructed from a kinetic analysis showed a reduction in the net flux of rhodamine 123 in the
presence of 0.1% w/v of Cremophor EL. The efflux transport was inhibited by Cremophor EL in
a noncompetitive manner based on a decrease in Vmax but constant Km. One plausible explanation
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for this observation may be that there is a direct interaction between rhodamine 123 and
Cremophor EL, perhaps through a micellar effect. According to the manufacturer (MilliporeSigma,
Burlington, MA), the critical micelle level for Cremophor EL is around 0.02% w/v, whereas it was
around 0.04% using an ultrasonic method60. Rhodamine 123 could be incorporated in micelles
that are too larger to traverse the intestinal barrier.
Effects of Cremophor EL on other transporters including oligopeptide transporters and
monocarboxylic acid transporters were also examined. Shono et al. did not detect any significant
changes in the transport of 3-O-methyl-D-glucose and Glycylsarcosine (Gly-Sar) suggesting that
Cremophor EL has no impact on both glucose and oligopeptide transporters58. Similarly, no
changes was observed in the transport of Gly-Sar across Caco-2 cell monolayers, but inhibition of
monocarboxylic acid transporter-mediated influx of benzoic acid was reported with a
concentration-dependent relationship (0.01 and 1.00 mM, rs = -0.94)53. After oral administration
of digoxin formulated with Cremophor EL (drug: 0.25 mg/kg, excipient: 1 mg/kg in rats), a
reduction of Cmax was associated with a shift of Tmax to a higher value and a decrease in AUC
measured over 8 hours54.
1.2.5 Poloxamers
Another class of nonionic excipients composed of the PEG group are Pluronic block
copolymers or poloxamers. In a single uptake study conducted by Bogman et al using P388/mdr
cells, Pluronic PE 6100 had an IC50 value of 0.01% w/v while Pluronic PE 8100 has a much small
smaller IC50 value at 0.002% w/v57. Batrakova et al. reported that addition of Pluronic P85 resulted
in significantly enhanced permeability coefficient of AP→BL transport for all four drugs
(fluorescein, doxorubicin, etoposide, paclitaxel and 3’-azido-3’-deoxythymidine) tested in Caco2 cell monolayers61. In MDCK-MDR1 cells, Pluronic P85 also led to enhanced accumulation of
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nelfinavir comparable to the level found in wild-type62. Pluronic F88 and F127, on the other hand,
did not show any significant increase in cell accumulation. Furthermore, a significant reduction of
47% in digoxin efflux was demonstrated in a diffusion chamber when 0.01%, w/v of P85 was
added48.

1.3

Effects of HLB and Other Structural Features on SAR
Structural features including hydrophilic-lipophilic balance (HLB) and the length of the

ethylene oxide group have been considered as important factors in the modulation of transporter
function. Relationship between hydrophilic and hydrophobic groups on the surfactant molecule
can be expressed using the HLB value, which is proportional to the solubility of the surfactant in
water. The HLB system, a numerical scale from 1 to 20, is an indication of the surfactant
functionality. Hydrophilic surfactants have HLB values greater than 10, while surfactants with
HLB values less than 10 are considered hydrophobic.
A number of studies were conducted to determine a potential correlation between the
properties of surfactant and its inhibiting effects. It was suggested that a structure-activity
relationship (SAR) may lead to the surfactant-induced inhibition of transporters52,63. The P-gpmediated efflux of epirubicin was inhibited using excipients with optimal HLB between 10 and 17
in Caco-2 cells and excised rat intestine64. The excipients were polysorbate 80, polysorbate 20,
polyoxyethylene (40) stearate and polyoxyethylene (23) lauryl ether. An approximately 50%
reduction in BL→AP secretory transport of epirubicin was observed when 200 µM of polysorbate
80 was added to the donor compartment of Caco-2 cells. The treatment using polysorbate 80 also
led to a simultaneous 2-fold increase in AP→BL absorptive transport. These changes were similar
to the impact of verapamil on the transport of epirubicin across the cell monolayers. Polysorbate
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80 provided the highest increase in the drug absorption in both Caco-2 cells and everted gut sacs
of rat.

Figure 1.1. Different functionalities of surfactant based on HLB scale from 0 to 20. Lipid
emulsion can be obtained as oil-in-water (o/w), water-in oil (w/o) or multiple emulsions (o/w/o
and w/o/w). In SEDDS, solubility enhancement of lipophilic drugs can be achieved with oil-in
water emulsions, in which surfactants are used as emulsifiers to improve their stability prevent
phase separation. It has been suggested that surfactants with different HLB values not only affect
the stability of the formulation but also lead to different level of toxicity. Multiple investigation
on the effect of HLB on surfactant-mediated inhibition of transporters and enzymes have
produced contradicting results as to whether the level of inhibition is dependent on HLB values.

Alternatively, in a separate study with everted gut sacs, Cornaire and colleagues did not
observe any obvious relationship between the P-gp inhibitory effects based on the transport of
digoxin and the HLB values of various surfactants such as TPGS 1000, Cremophor EL, Solutol
HS15, polysorbate 80 and polysorbate 20 in the range of concentration between 0.05 and 0.5%,
w/v54. While conflicting reports do exist regarding the effects of the HLB and transporter
effects, a lot of the same limitations/questions hold true including whether observations are due
to solubility effects vs. direct effects on the transporter(s) in question and whether or not the
observations are case specific for individual compounds. This is a critical question as there are a
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number of studies that have been conducted where the free drug solubility increases are not
measured and may be a confounding variable. This is particularly true when one considers that
many of the lipophilic compounds may actually be sequestered in micelles and an apparent
increase in permeation may be arising through a different transport route or through membranemicelle interactions as suggested by O’Driscoll6,7.

1.4

Effects of Micelle-Based Formulations on Oral Drug Absorption
About 90% of new chemical entities (NCEs) in the modern discovery pipeline are poorly

water-soluble65. Surfactants and polymeric micelles are often used in preformulation and
formulation studies to enhance drug solubility and achieve desired amount of dosage delivery in
both in vitro and in vivo screenings66,67. Surfactant-based formulations can be found in oral
administered products such as oral suspensions and soft or hard gelatin capsules. Additionally,
surfactants and amphiphilic polymers are utilized in oral lipid-based formulations like selfemulsifying drug delivery system (SEDDS) as a solubilizing agent in combination with cosolvent
and lipid components68,69. SEDDS and related strategies drug solubilization effects through
micelle-based formulation will be discussed along with the indirect effects elicited by the
excipients. These indirect effects can impact various properties of the in vitro cell culture models
and subsequently lead to changes in the experimental outcomes such as the apparent drug
absorption. It is a crucial that the difference in the environmental conditions are considered to
establish a correlation for in vitro and in vivo studies. Later in this section, physiological
considerations will be provided to identify and manage the shortcomings of in vitro model
compared to in vivo conditions.
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1.4.1 Intestinal Drug Solubilization of Micelle-based Formulations

Figure 1.2. Micelle formation at CMC in aqueous solution with hydrophobic core containing
drug molecules and hydrophilic segments on the outside interacting with water molecules.

At the CMC, micellar core formation occurs based on association between hydrophobic
segments of the surfactant in aqueous solution accompanied with the encapsulation of lipophilic
drug molecules70,71. The rearrangement of the hydrogen bonding network in the aqueous system
between water molecules and hydrophilic groups around the hydrophobic shell produces a
decrease in the surface free energy, which is the driving force for micelle assembly72. An
alternative explanation for solubility enhancement in the presence of surfactants and polymeric
micelles can be derived from the preferential hydration and/or the exclusion model for proteins as
reported by Timasheff and colleagues73. In this case, the hydrophobic regions of the polymer
preferentially bind to drugs, and exclude water through van der Waal interactions. The binding of
the hydrophobic drug region then minimizes the hydrophobicity of the polymer and the drug,
whereas their hydrophilic surfaces will enable increased drug solubility by forming a hydrated
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complex. This will result in the formation of a limited mobility hydrogen bonding surface leading
to the Liquid-Liquid Phase Separation74. The overall solvent accessible surface area capable of
hydrogen bonding combined with the hydrophobic surface area enabling drug interactions will
result in the net solubility enhancement achieved in a case by case manner.

Figure 1.3. Schematic representation of (A) preferential binding; (B) preferential hydration in
equilibrium dialysis. Reproduced with permission from Na and Timasheff, 198175.

Polymers like HPMCAS, which have a relatively higher hydrophobic binding capacity
compared to similar polymers, can maintain drug supersaturation in solution leading to an increase
in dose level and overcoming the solubility limit76. The drug absorption is then dictated by the
drug-polymer dissociation kinetics, the solubility of the free drug in the bulk fluid and the
permeability coefficient77,78. In such a case, supersaturation may cause transporter affinity and
capacity to reach the saturation level thus intensify the effects from transcellular permeation
provided the free drug concentration in solution stays well above the saturated affinity (Km) and
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capacity (Vmax/Jmax) for the transporter. This has been commonly seen when concentrationdependent permeability or absorption is measured79. In fact, any excipient-enhanced free drug
solubility could result in alteration in drug absorption across a biological membrane by saturating
counter absorptive and efflux pumps. Additionally, enzymes within the cells may also become
saturated if the permeability is rapid and the drug is quickly taken up into the cells cytoplasm.
Alternatively, one can envisage the scenario where the drug-polymer binding is too strong,
thus lowering the free drug concentration in the lumen. In this case, dissolution/solubility limited
absorption will occur. This would be analogous to the effects observed with highly protein bound
drugs in circulation. In this case, if the solubility measurements do not account for the bound and
unbound fractions, it is quite possible that despite an observed apparent increase in solubility will
result in potentially lower absorption compared to other systems. Since all of these situations are
plausible, further in vitro and in vivo research is required to delineate the solubilizing effects and
the impact on the free drug concentrations.
1.4.2 Other Factors in Surfactant-Mediated Absorption Enhancement
Increased solubility coupled with transporter inhibition are among multiple factors creating
a shift in drug absorption toward the potential lipophilic-favoring passive transcellular
mechanism80,81. Other potential mechanisms may include micelle association with lipid bilayer
resulting in increased fluidity and favoring permeability of lipophilic drug as well as lymphatic
absorption reported by O’Driscoll and colleagues6,82. This raises the compelling case that some of
these surfactants may actually increase mixed micellar solubilization of certain drugs which to our
knowledge have not been comprehensively investigated. The accompanying events could
potentially lead to enhanced solubility through a lipid-based, micellar solubilization mechanism
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and potentially lead to the internal saturation of efflux transporter binding sites as discussed in the
following section.

Figure 1.4. Effects of micelle-based (and lipid-based) formulation on drug absorption.

Solubilizing excipients are also known to indirectly cause other changes which may result
in modulation of drug transports and other cellular performances. Toxicity-related effects due to
unwanted activities of excipients such as osmotic (PEG’s) and apoptosis inducing (TPGS)
properties. While the literature suggests that PEG may cause an effect on efflux, the effects on
osmotic pressure and the indirect interactions with red blood cell membranes has to be factored in
as a potential confounding influence in some studies83. There is also the potential for PEG
derivatives to change the dielectric constant of water and enhance solubility, which may lead to
saturation of transporters and increase the passive transcellular delivery. There is a concern
regarding the utilization of low levels of excipients like TPGS 1000 when during process scale up
the low concentration required for absorption enhancement necessitates its concentration remain
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constant along with the dose. Moreover, the exact mechanism of interaction that leads to an
increase in absorption remains unknown. Some studies have suggested that TPGS may rigidize a
membrane, although the solubilization effects of TPGS 1000 may also be a very important driver
of the reduced efflux effect54.

1.5

Mechanism Underlying the Modulation of Transporter Activities by Polyethoxylated
Excipients
Although functional effects of these excipients have been demonstrated, the exact

mechanism leading to the inhibition of drug transport and metabolism remains unclear. A number
of possible mechanistic routes have been proposed including interaction of surfactant molecules
with transporter at the substrate or nucleotide binding sites causing a decrease in ATPase activity.
Other non-transporter related impacts have also been investigated such as changes in plasma
membrane integrity and interference with other proteins such as protein kinase C that work to
enable the biological activities of the transporters. It is possible that the inhibition is a result of
multiple underlying mechanisms, which may vary from one excipient to another.
1.5.1 Effective Concentration and CMC
Changes in transport of P-gp substrates have been observed even below the CMC level and
without micelle solubilization suggesting that (a) surfactants may elicit inhibitory effect via other
pathways prior to transporter/ enzyme saturation and (b) the surfactant-induced inhibition is
associated with the free monomer rather than the micellar form of the surfactant. TPGS blocked
the efflux activity of P-gp starting at concentration level far below its CMC52. On the other hand,
the fraction of free surfactant molecules is reduced upon micelle formation at concentrations above
the CMC level, which can lead to a reduction in inhibitory effect. As a result, the absorption of Pgp substrates (i.e. rhodamine 123) as a function of Cremophor EL concentration exhibited a bell-
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shaped curve. That said, this is not true for some excipients which induce inhibition of transporters
at both below and above CMC. This continued increase in inhibitory effect might be due to
increase in CMC in the presence of cells and other substances. It has so been argued that even
though there is a decrease in the amount of free surfactant molecules above the CMC level, the
remaining monomers might still be sufficient for inhibition to take place.
In addition, transport of surfactants across the intestinal membrane are considered to occur
in the monomeric form and not as intact micelles84. While vesicle-mediated uptake of micellar
form has been demonstrated in various cells and tissues, it has yet to be confirmed in the intestinal
cell models. This may be attributed to the presence of unstirred water layer (UWL) and intestinal
mucus, which separate the phospholipid bilayer from the bulk fluid phase of the lumen. Molecular
diffusion across UWL are thought to be the rate-limiting step for drug transport in Caco-2 cell
monolayers85. In lipid-based drug delivery system, lipophilic components may undergo
dissociation within the UWL prior to membrane partition during which concomitant absorption of
released drug molecules may take place via passive transcellular route86. Addition of mucolytic
agent resulted in a 22.5-fold increase in intestinal absorption of FD-4 compared to standard
samples containing only TX-100 micellar system87.
1.5.2 Modulation of ATPase Activity
An extensive mapping of particular regions on P-gp capable of interacting with drug
molecules has been constructed based on advances in scientific research for localization of
substrate interaction23. Multiple drug-binding sites have been identified using photo affinity
analogues and region-specific antibodies supplemented with site-directed mutagenesis. The
previous knowledge of characteristics and functional modes of P-gp has allowed researchers to
design various experimental techniques in order to elucidate the interaction between polysorbate
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this efflux transporter and its substrates/ inhibitors88,89. The basal and drug-stimulated ATPase
activity assessment have been used as an alternative approach to the conventional screening
assays90. P-gp-mediated drug efflux is closely-coupled with ATPase activity. The ATP-binding
domains of P-gp act as ATPases by converting ATP into ADP and providing the energy needed to
pump the substrates across the plasma membrane and against the concentration gradient. When
Kimura and coworkers studied the effect of cholesterol on drug-stimulated ATPase activity of Pgp, they found a strong correlation with molecular weight of the drugs used as the stimulators. The
results showed that cholesterol increased the affinity of smaller drugs with molecular weight less
than 500 Da, and may play a role in the recognition of these drugs by P-gp91.
Several studies have been conducted to investigate the alteration of drug-induced ATPase
activity by surfactants and emulsifying polymers. Batrakova et al. used Vin (simeticone) to study
the effect of Pluronic P85 on the interaction bepolysorbate P-gp and the drug molecule based on
modulation of Vin-induced ATPase activity92. The results showed that Pluronic P85 lowered the
activity of ATPase in a concentration-dependent manner. Pluronic P85 exhibited the highest
inhibition potency in ATPase activity of P-gp, with 120-fold increase in Vmax/Km ratio, compared
to MRP1 and MRP2 which had 14 and 6 times increases respectively. Furthermore, the inhibition
of surfactant on drug-induced ATPase was also observed with TPGS analogs. Collnot et al. did
not observe any significant changes in ATPase activity when TPGS was incubated with artificial
ATP containing membranes from Sf9 insect cells in the absence of drug. However, they found that
inhibition of verapamil-induced ATPase activity increased as a function of TPGS 1000
concentration level added. While TPGS 1000 did not significantly alter ATPase activity without
any P-gp substrate present, it blocked the efflux transport of verapamil in a dose-dependent manner.
IC50 values varied for different P-gp substrates such as progesterone (3.25 µM), verapamil (3.18
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µM), quinidine (0.82 µM), and only 0.40 µM of TPGS 1000 was required to inhibit ATPase
activities stimulated by nicardipine.
Further experiments employing UIC2 shift assay was conducted to evaluate the TPGSinduced P-gp ATPase inhibition93. UIC2 is a sensitive P-gp antibody that is highly reactive during
substrate binding and becomes less reactive when ATP level is depleted or nucleotide-binding site
is affected by mutation. Therefore, UIC2 shift assay is useful for monitoring P-gp functional state.
It has been used to demonstrate that reactivity of UIC2 with P-gp was significantly raised in the
presence of P-gp substrates including cyclosporine, verapamil and rhodamine 123. Although the
reactivity of UIC2 was shifted to a lower level when TPGS 1000 was added along with the
substrates, the decrease is statistically insignificant and suggesting that competitive inhibition
might not be the main contributor. Direct interaction bepolysorbate surfactant and polymer
molecules with P-gp is unlikely, and other mechanism such as changes in plasma membrane
integrity, disruption of mitochondria and inhibition of PKC have been considered.
1.5.3 Modulation of Phospholipid Bilayer
Gross morphological changes were not observed at the concentration range where
modulation of drug transports was detected. The presence of excipients did not have any effect on
the cellular tight junction integrity of Caco-2 cell monolayers based on assessment using passive
paracellular marker (i.e. D-mannitol) and measurement of the transepithelial electrical resistance
(TEER) values. In most cases, the results collected from cytotoxicity assays such as MTT (3-(4,5Dimethylthiazol-2-yl)-2,5 Diphenyltetrazolium Bromide) and LDH (lactate dehydrogenase) did
not correlate with the inhibitory effects exhibited by the excipients. It has been suggested that
surfactants and emulsifying polymers modulate the activities of the enzymes and transporters by
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causing subtle changes in the plasma membrane rather detrimental damages associated with
cellular toxicity.
P-gp is a 170 kDa transmembrane protein expressed in the gut wall and other barrier-like
tissues. It has a duplicated structure containing six membrane-spanning segments in each half94.
Surfactants are known to induce changes in the fluidity of plasma membranes95, which may have
indirect impact on activities of P-gp and other membrane transporters due to conformational
changes in the secondary and tertiary structures96–98. Fluorescence polarization and a more recent
method using electron spin resonance (ESR) spectroscopy have been utilized to investigate the
effects of excipients on plasma membrane anisotropy99,100. Diphenyltriene (DPH) and its anionic
counterpart, trimethylamine-diphenyltraiene (TMA-DPH) are used as fluorescence labeling
probes because they can intercalate into the hydrophobic core and the polar head regions,
respectively. Cholesterol can act as a rigidizer, whereas benzyl alcohol is documented as fluidizer
of cell membrane. Both of these compounds are commonly used as positive controls in the
measurement of fluorescence anisotropy, which is inversely proportional to membrane fluidization.
In a membrane fluidity study performed using DPH and TMA-DPH, Dudeja and colleagues
observed a decrease in the fluidity of cell membrane when Cremophor EL was added to suspension
of drug-resistant cervical cells (KB 8-5-11)101. This means that the previously mentioned excipient
caused a decrease in the fluidity of both fatty side chain and polar head group regions. In another
study conducted by Hugger et al., there were no significant changes in the membrane fluidity of
Caco-2 and MDR1-MDCK cell lines upon addition of Cremophor EL. Rege et al. reported that
Cremophor EL and Polysorbate 80 caused a significant increase in fluidization of Caco-2 cells
when DPH was used as the fluorescent label for changes in the hydrophobic region of the plasma
membrane. The contradictory findings are not uncommon amongst this type of studies, where
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different cell lines, concentration range etc. were adapted making it impossible to compare two
individual studies of the same method. For instance, the addition of Polysorbate 80 did not result
in any changes in fluidity when Caco-2 cells were used, but it caused an increase in fluidity for
polar head groups in MDR1-MDCK cells at concentration above its CMC.

Figure 1.5. Potential mechanistic routes for transporter inhibition. (1) Decreased ATPase
activity. (2) Modulation of plasma membrane (3) Inhibition of protein kinase C (PKC).

Besides differences in experimental settings from one study to another, method sensitivity
and precision might be a possible shortcoming associated with fluorescence polarization. TPGS
increased the anisotropy of DPH which means the hydrophobic portion of the phospholipid bilayer
was rigidified in the presence of this excipient; yet no significant change was detected for the
anisotropy when TMA-DPH was used.44 According to the an investigation on excipient-induced
membrane alteration detected using ESP spectroscopy, TPGS exhibited membrane disruption at
concentration levels much higher than those associated with the inhibition of P-gp efflux102. As
demonstrated by Collnot et al., changes in membrane fluidization was only detectable when TPGS
1000 concentration above 3.33 M was added, which correspond to the cytotoxic level found using
LDH release assay. The substantial gap between polysorbate the concentration at which inhibition
and membrane modulation were initially detected indicates that TPGS does not inhibit P-gp by

24
changing the fluidity of cell phospholipid bilayer. However, this does not exclude undetectable
changes in the microenvironment of the membrane associated with P-gp. Another possible
explanation to this is surfactant molecules become embedded in the plasma membrane and create
a steric hindrance preventing drug from entering substrate binding site on P-gp efflux transporter.
1.5.4 Inhibition via reduction of protein kinases
Active transport system uses free energy released from conversion of ATP into ADP.
Protein kinases function to phosphorylate many proteins that uses ATP as the energy source
including members of the ABC transporter superfamily. P-gp, for example, cannot function
without phosphorylation by protein kinases C, which converts ADP back to ATP. Transport of
rhodamine 123 across Caco-2 cell monolayers was shown to be unaffected by the addition of
protein kinase C (PKC) inhibitors like staurosporine and chelerythrine chloride suggesting that the
excipients effects on active transporters is not related to PKC activity54.

1.6

Conclusions
In our review of the literature, for the excipients reviewed it appears that the trend in

excipient effect, if any, is to increase absorption from the GI tract either by enhancing solubility,
altering the membranes, blocking efflux transporters or a combination of processes. We have also
observed several studies that suggested indirect effects of the excipients on transporter kinetics.
Some studies have suggested that there may be possible changes in ATPase activity, membrane
fluidity and critical regulatory protein like protein kinase C. These mechanisms along with
increased solubility appear to be the likely rationale behind increase permeability and absorption,
whereas direct transporter interaction do not appear to be feasible. It cannot be ruled out that a
change in the membrane fluidity may be also change the conformation of the transporter and alter
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its function. Therefore, indirect effects on the transporters and potential regulatory pathways
maybe be occurring, however this an area of considerably debate and further research is required
to determine the exact mechanism by which some of these transporters are being altered. In
conclusion in each of these cases, a direct effect on the transporter has not been reported and to
our knowledge as such, “pharmacological activity” of excipient has yet to be seen.
Based on our review it appears that solubility enhancement and/ or transient effects on the
transporters predominate to increase absorption. Based on extensive literature assessment, the
surfactants reviewed here should be considered as safe with non-deleterious effects that enhance
the exposure of the mitigating agent as result in lower cost for patients. Patient welfare should be
prioritized in a cost-effective manner. The failure to associate toxicity with the amount of
excipients added suggests that this agent are providing beneficial effect in term of patient exposure.
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EFFECTS OF DENDRIMER-LIKE BIOPOLYMERS ON
PHYSICAL STABILITY OF AMORPHOUS SOLID DISPERSIONS
AND DRUG PERMEABILITY ACROSS CACO-2 CELL
MONOLAYERS

Modified with Permission From: Lavan M, Knipp GT.
Effects of Dendrimer-Like Biopolymers on Physical Stability of Amorphous Solid Dispersions
and Drug Permeability across Caco-2 Cell Monolayers.
AAPS PharmSciTech (In Press)

2.1

Introduction
Starch is a natural polymer that has been extensively used in the pharmaceutical industry1.

Its processability, biocompatibility and acceptance by the regulatory agencies make it a suitable
excipient for a wide array of applications including serving as a filler, binder, emulsifier, and
thickening agent2–5. Amylose and amylopectin are the major components of starch, where the
composition of these two α-D-glucan molecules varies according to the plant species6. Amylose is
a linear chain of glucose molecules linked together through α-1,4 glycosidic bonds. In contrast,
amylopectin has a regular branching pattern due to the formation of α-1,6 glycosidic bonds. A
deficiency in starch debranching enzymes (DBE) associated with plant genetic mutation was found
to result in the synthesis of a water soluble and highly branched form of α-D-glucan, called
phytoglycogen7.
The sugary-1 mutant of maize produces phytoglycogen instead of starch due to
compromised activity of an isoamylase-type DBE known as SU18. The maize kernel is the largest
source of phytoglycogen, and the extraction technique has been described in literature9.
Phytoglycogen is a dendrimer-like biopolymer (DLB), where the core-shell structure enables the
formation of carbohydrate-based nanoparticles. Similar to dendrimers, phytoglycogen and its
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derivatives can interact with drug molecules and potentially act as a stabilizing and solubilizing
agent in the formulation of poorly water-soluble drugs. For example, Chen and coworkers
demonstrated that the addition of phytoglycogen in the formulation of quercetin led to a reduced
crystallinity of the solid dispersion, improved drug apparent solubility (Solapp) and enhanced transepithelial drug transport10. However, one particular issue that has as of yet been unresolved is
determining the difference between the free drug in solution and that complexed within the
dendrimer. It is only the free drug in solution that is available to permeate the epithelial barrier
and be absorbed.
It is possible to fine-tune the stability and/or solubility enhancing effects of phytoglycogen
via its interaction with drug molecules by utilizing property based chemical modifications that can
tailor the surface properties for specific drug association. Some examples of these techniques
include internal space enlargement using β-amylase controlled hydrolysis and hydrophobichydrophilic adjustment via attachment of different functional groups to the interior region or the
outer surface of phytoglycogen11. Recent advances in the chemical processing of the starch have
facilitated the modification of native starch into many derivatives possessing different
physicochemical properties12,13. Phytoglycogen has been reported to be susceptible to these
modifications as well14. In an experiment conducted by Scheffler et al, octenyl succinate grafted
starch and phytoglycogen were prepared14,15. The resulting phytoglycogen octenyl succinate was
found to have a lower digestibility and improved emulsification properties compared to the
derivative prepared from waxy corn starch. Introduction of negative charges and lipophilicity were
also obtained via octenyl succinylation - both of which are adjustable based on the degree of
substitution (DS)16. Such modifications may enable the selection of a phytoglycogen derivative
with increased loading capacity for the particular drug of interest and provide favorable water
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interactions on the surrounding surface. Moreover, the release rates of the free drug concentration
may also be fine-tuned as well.
A disruption in the crystalline lattice of a therapeutic entity by random distribution in
polymers will generally enable the formation of a higher energy amorphous form with increased
water solubility17. To maximize the drug absorption across the intestinal epithelium, where either
solubility or dissolution limited behavior is observed, supersaturation must be sustained in the
gastrointestinal tract to increase absorption. However, the amorphous state is a thermodynamically
unstable form, which can be readily converted to a lower energy crystalline material negating the
solubility advantage associated with supersaturation depending on the rates of nucleation kinetics
comparative to polymer association18. Polymeric matrices are therefore typically selected to
maintain the physical stability of the amorphous form during production, storage and for increasing
the intestinal supersaturation for a prolonged period by analyzing the polymer’s potential to inhibit
crystallization. The addition of a polymeric carrier can lead to a reduction in the molecular mobility
and an anti-plasticization effect associated with the increase in the glass transition temperature.
The intermolecular interaction of drug is interrupted by the formation of drug-polymer interaction
in polymeric-based ASD.
The addition of polymeric excipients (e.g. HPMCAS, PVPVA and Soluplus®) have
traditionally been used as a formulation strategy to combat the stability issues in amorphous solid
dispersion (ASD) formulation19–22. The polymer can act as a crystallization inhibitor and
potentially increase amorphous stability during storage and upon exposure to an aqueous
environment. In these systems, the drug molecules are dispersed within the polymeric matrix, and
the intermolecular interaction between the drug and polymer plays an important role in hindering
the crystallization of amorphous solid. The presence of a hydrophilic polymer can also lead to an
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increased Solapp of the molecularly dispersed drug over the neat amorphous form. Biomaterialbased excipients made from phytoglycogen can provide an alternative approach to solving stability
and solubility related problems for lipophilic drug compounds in ASD formulation. This new
technology may potentially become a useful tool to mitigate challenges (e.g. toxicity, limited drugexcipient interaction etc.) associated with synthetic dendrimers and other currently available
polymers23.
The main goal in this study is to evaluate the potential application of proprietary DLB
compounds (generously donated from Phytoption LLC, West Lafayette, IN; chemical structures
not disclosed) as polymeric excipients by focusing on the changes in the physical stability and
assessing the in vitro cellular absorption potential of the free fraction of lipophilic drugs in these
binary ASD systems. It should be noted that the dendrimers were provided for proof of concept
research to investigate heterogeneous carriers for the different agents and their potential. The
following experiments were conducted in the study to compare the performance of three
phytoglycogen derivatives - DLB1, DLB2 and DLB3 - with commercially available excipients
including HPMCAS, PVPVA and Soluplus® to: (1) to perform PXRD to analyze formation and
physical stability of ASD formulations, (2) to determine mitochondrial-based toxicity using the
MTT assay and investigate the potential effect of DLB’s on cellular viability and (3) to assess drug
permeability and flux across Caco-2 cell monolayers.
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2.2

Materials and Methods

2.2.1 Materials
The amorphous solid dispersions were prepared and generously provided by Phytoption
(West Lafayette, IN). Drug compounds (niclosamide, celecoxib, and resveratrol), HPMCAS,
PVPVA (Kollidon® VA 64), Soluplus® and DLB excipients were supplied by the same provider.
Fetal bovine serum (FBS), penicillin-streptomycin, nonessential amino acids (NEAA), trypsinEDTA, Dulbecco's Modified Eagle Medium (DMEM), Hank’s balanced salt solution (HBSS),
Phosphate buffer saline (PBS) and 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide (MTT) reagent were purchased from Sigma Aldrich (St. Louis, MO). L-glutamine was
purchased from Mediatech, Inc. (Herndon, VA). Polystyrene T-75 culture flasks, Transwell®
permeable supports, and all other supplies were obtained from Corning, Inc. (Corning, NY). Caco2 cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA).
2.2.2 Powder X-ray Diffraction (PXRD)
PXRD patterns for the amorphous solid dispersions were developed using Rigaku
SmartLab X-ray diffractometer (Rigaku, Inc. The Woodlands, TX) equipped with a Cu-Kα
radiation, and operated at 40 kV and 40 mA. The samples were scanned from 5˚ to 40° 2θ at a
speed of 2° per minute with 0.04° step size. To access the amorphous stability of the formulations
over time, the samples were also analyzed at 2 and 4-week times after being stored at 40°C and
75% relative humidity (RH). The PXRD patterns were also obtained for crystalline drugs in the
absence of the excipients for reference.

40
2.2.3 Cell Viability Assay
Caco-2 cells (passage 55) were seeded at 30,000 cells/well in 96-well plate coated with
collagen type I. Medium replacement took place every two days. MTT was conducted after 3 days,
when the cells reached approximately 95% confluency24,25. Next, the media were removed, and
the cells were washed with PBS. HBSS containing appropriate amounts of native or modified
phytoglycogens was added. After a 3-hour incubation, 20 μL of MTT (5 mg/mL in HBSS) were
added to the cells. After an additional 4 hours of incubation, HBSS was removed, and 100 μL
solution of dimethyl sulfoxide was added followed by overnight agitation. The absorbance was
measured at 560 nm. Cell viability can be calculated based on the ratio between treated and
untreated (control) cells.
𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =

𝐴𝑏𝑠. 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
× 100
𝐴𝑏𝑠. 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙𝑠

2.2.4 Permeability Studies
Caco-2 cell monolayer permeability studies were conducted using the same procedure as
described by Roth et al26. Briefly, Caco-2 cells were grown in DMEM supplemented with 10%
FBS, 1x nonessential amino acids, penicillin-streptomycin, and 2 mM glutamine. The cells were
incubated at 37°C, 5% CO2 and 90% RH. To maintain the cell culture, the medium was changed
every two days and cell passaging was performed at 80 – 90% confluence. With respect to the
permeability study27,28, the cells (passage 47 to 51) were seeded on a polyester membrane treated
with collagen at a density of 8 x 104 cells/cm2. All permeation studies were conducted using Caco2 cell monolayers at 21 to 25 days post seeding. The Transepithelial Electrical Resistance (TEER)
measurements ensured the integrity of the cellular barrier (data not shown). Prior to the transport
experiment, the residual compounds were rinsed off a couple of times using PBS following the
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culture medium removal. The cell monolayers were then incubated for 10 min with a third rinse
of HBSS at 37˚C immediately before the study.
The samples were prepared by adding 10 g of ASD to 10 mL of HBSS followed by vortex
mixing at 37˚C for 20 minutes. After centrifugation at 10,000 g for 10 minutes, the supernatant
was added to the donor (apical) compartment with fresh HBSS in the receiver (basolateral)
compartment of the Transwell®. Samples were subsequently collected at 30, 60, 90, 120 and 180
minutes from the basolateral compartment for analysis. The remainder of the supernatant was used
to measure the initial donor concentration. The drug concentration at each sampling time was then
determined using HPLC on an Agilent 1100 Series HPLC system coupled with an UV-vis detector.
A reverse phase C18 column 250 x 4.6 mm, 5 µm was used as the stationary phase with a constant
flow rate of 1 mL/min. Isocratic elution was used for niclosamide, celecoxib and resveratrol with
water to acetonitrile ratio of 40:60, 40:60 and 65:35, respectively. The mobile phase was prepared
using filtered distilled-deionized water and HPLC-grade acetonitrile with 0.1% of formic acid
added to both components. The UV absorption wavelengths were 244 nm for niclosamide, 254 nm
for celecoxib and 303 nm for resveratrol. The drug concentration was determined using standard
curve based on the AUC value of the appropriate peak. The experiment was conducted under sink
condition for all the samples over a 180-minute duration except for the samples containing
crystalline drugs, celecoxib-PVPVA and resveratrol-Soluplus®. The drug concentration in the
receiver compartment was below 10% of the donor compartment concentration, sink conditions
were fulfilled and the apparent permeability coefficient (𝑃𝑎𝑝𝑝 ) was calculated using the following
equation.
𝑃𝑎𝑝𝑝 =

𝑑𝑀⁄𝑑𝑡
𝐶0 ∙ 𝐴
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The steady-state appearance rate of drug (𝑀 ) in receiver compartment is denoted by
𝑑𝑀⁄𝑑𝑡, 𝐶0 represents the initial concentration in the donor compartment, and 𝐴 is the surface area
of the filter membrane. Alternatively, a general equation that does not require sink condition was
also used to calculate the 𝑃𝐴𝑝𝑝 by nonlinear curve fitting of the experimentally measured
concentrations with the predicted values. The concentration of drug in the receiver at time, 𝑡 is
denoted by 𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟 , 𝑡. 𝑄𝑡𝑜𝑡𝑎𝑙 is the total amount of drug in the system, 𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟 is the volume of
the receiver and 𝑉𝑑𝑜𝑛𝑜𝑟 is the volume of the donor. 𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟 , 𝑡 − 1 is the receiver concentration at
the previous time point, and ∆𝑡 is time interval. The sample replacement factor, 𝑓 = 1 −
𝑉𝑠𝑎𝑚𝑝𝑙𝑒 ⁄𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟 . In each experiment the mass balance was determined and a total recovery of
greater than 95% of the drug put into the system was recovered in all cases, suggesting cell uptake
was not appreciable.
𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟 , 𝑡 =

𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟 + 𝑉𝑑𝑜𝑛𝑜𝑟

+ [(𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟 , 𝑡 − 1 × 𝑓) −

𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟 + 𝑉𝑑𝑜𝑛𝑜𝑟

]×𝑒

−𝑃𝑎𝑝𝑝 ×𝐴×(

1
1
+
)×∆𝑡
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟 𝑉𝑑𝑜𝑛𝑜𝑟

Permeability is a rate-based measurement that needs to be expanded to determine the
effects of the Solapp enhancement provided by the formulation within the apical compartment,
which represents the intestinal lumen in a simplified in vitro model. Therefore, to approximate
formulation effects on drug absorption, flux needs to be described as the amount of drug
transported across the Caco-2 cell barrier over a unit area and time. The values for flux (𝐽) can be
calculated for transport of drug from the apical to basolateral compartment by multiplying the
initial concentration and permeability coefficient.
𝐹𝑙𝑢𝑥 =

𝑑𝑀⁄𝑑𝑡
= 𝐶0 ∙ 𝑃𝑎𝑝𝑝
𝐴
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2.2.5 Statistical Analysis
Statistical analysis was conducted using one-way ANOVA for all pair-wise comparision of
C0, Papp and flux values between two different formulations of the same drug compound with
Scheffe’s method testing on SAS (Cary, NC). A p-value of <0.05 was considered statistically
significant.

2.3

Results
Niclosamide, celecoxib and resveratrol are moderately hydrophobic with high melting points.

These compounds can form hydrogen-bond complexes, thus having fairly high tendencies to
nucleate and recrystallize in solution. Beside its anti-parasitic activity, niclosamide has also been
shown to exhibit antiviral and anticancer effects according to recent investigations29,30. Celecoxib
is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2
(COX-2) enzyme and prevents the conversion of arachidonic acid into prostaglandin proinflammatory precursors31. Resveratrol is naturally produced in grapes and well-known for its
cardioprotective and anticancer attributes32. The solubility advantage of amorphous formulations
is associated with the lack of long-range order in their solid-state properties. In general, an
amorphous system has a higher free energy level in relation to the crystalline form providing it
with a tendency to nucleate and then recrystallize in order to reach a thermodynamically more
stable state33. Polymeric excipients can be added as a matrix to inhibit crystallization via
interactions formed between highly dispersed drug molecules and the polymer17,34.
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2.3.1 PXRD Characterization and Physical Stability of Amorphous Dispersions
In this study, three commercially available polymers, namely HPMCAS, PVPVA and
Soluplus®, were used as polymeric matrices to contrast with the novel DLB polymers to develop
amorphous dispersions of the model compounds. For each compound, two of the commercially
available polymers were used along with a novel DLB polymer where the chemistry was modified
to enhance the carrying capacity for each specific drug (proprietary information of Phytoption,
LLC.) The crystallinity of the formulations was assessed using PXRD. This technique was also
used to detect crystallization occurring in the ASD formulations during storage of the respective
formulations for 2 and 4 weeks at 40°C/75% RH. Figure 2.1 shows the powder X-ray patterns
(PXRD) of pure unprocessed API’s and ASD’s containing different excipients. The diffraction
pattern of drug-polymer dispersions exhibited an “amorphous halo” in place of Bragg peaks
suggesting that they were “X-ray” amorphous. The absence of crystalline peaks strongly supports
the formation of ASD for niclosamide, celecoxib and resveratrol.
In order to investigate the inhibitory effects of the polymeric excipients on crystallization,
two sets of samples were taken from each formulation at 2 and 4 weeks after being subjected to
the storage treatments (40°C/75% RH). Peaks indicating crystallization were observed for
niclosamide ASD formulated with DLB1 and HMPCAS after 2 weeks, while the sample remained
in amorphous state for up to 4 weeks in the formulations containing PVPVA and Soluplus® (Figure
2A-B). For celecoxib formulations, a relatively low level of crystallization was observed in the
dispersion containing DLB2 at 2 weeks with no further change in the diffractogram at 4 weeks
post treatment (Figure 2C-D). Other excipients (i.e. HPMCAS, PVPVA and Soluplus®) did not
lead to crystallization of celecoxib within the 4-week period. The PXRD diffractogram of the
resveratrol-DLB3 dispersion revealed that crystallization took place within 2 weeks of storage at
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40°C/75% RH, similarly to the formulation containing HPMCAS (Figure 2E). While the spectrum
of resveratrol-PVPVA dispersion remained largely as an “amorphous halo” at week 2, there were
stronger Bragg peaks present at week 4, indicating that some crystallization may be occurring
(Figure 2F). crystallization for niclosamide, celecoxib and resveratrol with the Bragg peaks
appearing at less than 2 weeks after storage treatment at 40°C/75% RH.
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Figure 2.1. PXRD patterns scanned from 5˚ to 40° 2θ at a speed of 2° per minute for pure
crystalline drug and polymeric amorphous dispersions for (A) niclosamide, (B) celecoxib and
(C) resveratrol formulated with four different polymeric excipients.
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Figure 2.2. Effects of polymeric excipients (bottom to top: DLBs, HPMCAS, PVPVA and
Soluplus®) on the physical stability of niclosamide (A,B), celecoxib (C,D) and reseveratrol (E,F)
ASD formulations after 2 and 4 weeks of storage treatment at 40 °C/75% RH.
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Table 2.1 summarizes the presence of crystallization at different time points as detected by
PXRD for all the formulation tested. Interestingly, crystalline indicating peaks were not observed
over the 4-week storage time in all the formulations using Soluplus®. PVPVA was effective as a
crystalline inhibitor for the ASD of niclosamide and celecoxib, but peaks of crystallinity were
detected at 4 weeks for resveratrol formulation. The celecoxib-HMPCAS dispersion remained
physically stable for 4 weeks. The DLB compounds failed to inhibit residual crystallization for
niclosamide, celecoxib and resveratrol with the Bragg peaks appearing at less than 2 weeks after
storage treatment at 40°C/75% RH.
Table 2.1. Summary on the presence of crystallinity peaks (indicated by x) detected using PXRD
after 2 and 4 weeks of storage treatments at 40 °C/75% RH.
Excipient
API's

Time
DLB's

HPMCAS

PVPVA

Soluplus®

-

-

-

-

-

-

-

-

-

-

x

-

-

x

-

2 weeks
Niclosamide

x

x

4 weeks
2 weeks
Celecoxib

x
4 weeks
2 weeks

x

Resveratrol
4 weeks

2.3.2 MTT Assay for DLB Derivatives
MTT assay was used to assess the potential toxicity of DLB compounds on Caco-2 cell
monolayers. In living cells, MTT is oxidized by mitochondrial dehydrogenase into formazan,
which is dark blue in color35. Therefore, the amount of formazan produced is proportional to the
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mitochondrial lysis and generally accepted as a measurement of cell survival. A range of
concentrations up to 2,000 mg/mL was used, with an arbitrary toxic limit was assigned at 80%
viability compared to unexposed cells. Only DLB1 and DLB2 at 2,000 mg/mL were considered
toxic according to the assigned toxicity limit. It should be noted that the sample concentration used
to assess mitochondrial-related toxicity of MTT assay was 3 times higher than the level used in
the preparation of ASD samples for the Caco-2 permeability studies. These results suggest that
phytoglycogen and its derivative including DLB1, DLB2 and DLB3 developed for ASD
formulations for niclosamide, celecoxib and resveratrol have little to no effect on cellular viability
of Caco-2 cells in the permeability studies conducted (Figure 3).

Figure 2.3. The effects of DLB1, DLB2 and DLB3 on mitochondrial-based toxicity of Caco-2
cells. The limit of < 80% of cell viability comparative to the control cells was utilized as an
index for a cytotoxic effect.
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2.3.3 Changes in the Apparent Permeability Coefficient with Different Polymeric Excipients
In ASD formulations, the amorphous drug is molecularly dispersed within a polymeric
matrix to lower the chemical potential and induce the drug-polymer interaction. The presence of
the polymer can lead to disruption of solid state long range crystallization interaction and delay
the conversion from amorphous to crystalline form in an aqueous environment36. Although the
conversion from amorphous to crystalline form is inevitable, the main goal is to sufficiently
maintain supersaturation in the GI tract so that a safe and efficacious therapeutic drug level can be
achieved37,38. Crystallization is a two-step process starting with nucleation and followed by crystal
growth to form solid precipitates. Once supersaturation can no longer be maintained, the
concentration of the drug in the solution becomes equivalent to the solubility of the
thermodynamically more stable crystalline form18. If the permeation rate across the epithelial
barrier is sufficiently high, then the supersaturation state will be altered due to the resultant loss of
free drug through absorption. Alternatively, if crystallization takes place immediately upon contact
with water, the solubility advantage associated with the amorphous state is lost. Polymeric
excipients can act as crystallization inhibitors during dissolution to prolong supersaturation and
potentially enable higher absorption, except for permeability limited compounds39. To better
understand the consequences of ASD on drug absorption, the effects of the formulation on both
Solapp and Papp of the drug should be considered38.
To assess the balance between the ASDs and potential absorption enhancement, the
permeability and flux of each ASD formulation across Caco-2 cells were determined. The Caco-2
cell line was derived from a human colorectal adenocarcinoma and is a widely used model for
permeability screening in academia and industry26,40. The Caco-2 cells have long been utilized as
an in vitro model of the small intestine, where it is speculated that a majority of drug absorption
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takes place after oral administration41. In this study, the cells were cultured on a Transwell® filter
insert forming a monolayer and dividing the chamber into the apical and basolateral compartments.
Initially, the sample was added to the apical side (donor), and the amount of drug transported
across the cell barrier into the basolateral compartment was analyzed at 6 time points over a 3hour period. The ASD samples were prepared by adding 1 g of the amorphous blend per mL of
HBSS, followed by mixing and centrifugation to remove solid precipitates. The supernatants were
collected and used in the permeability studies and to determine C0 via HPLC analysis and a
standard curve of known concentrations. The apparent permeability coefficient, Papp values
calculated using the sink corrected equation and the general equation were similar for most samples
(see Table 2.2). The receiver concentrations of samples containing celecoxib and resveratrol in
crystalline form without any excipient were found to be at 18% and 10% of the donor concentration
at the final time point of 180 minutes, respectively. The Papp calculated using the general equation
was 11.6 x10-6 cm/sec for celecoxib and 25.4 x10-6 cm/sec for resveratrol, which were both higher
than the values obtained from the equation assuming sink condition. Table 2.3 shows the C0, Papp
and flux of all the formulations for niclosamide, celecoxib and resveratrol.
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Table 2.2. The apparent permeability coefficients calculated using the sink corrected equation
(Papp, 1) and the general equation 2 (Papp, 2). Papp (10-6 cm/sec);
ND: Not Detectable.
Drug

Excipient

Creceiver/Cdonor

Papp, 1

Papp, 2

None

-

N.D.

N.D.

DLB

<10%

0.23 ± 0.01

0.24 ± 0.01

HPMCAS

<10%

4.31 ± 0.23

5.71 ± 0.30

PVPVA

<10%

1.48 ± 0.04

1.58 ± 0.06

None

18%

4.22 ± 0.01

11.6 ± 0.26

DLB

<10%

1.78 ± 0.01

1.05 ± 0.02

HPMCAS

<10%

4.82 ± 0.29

4.55 ± 0.12

PVPVA

12%

4.03 ± 0.10

5.17 ± 0.22

None

10%

10.5 ± 0.01

25.4 ± 0.89

DLB

<10%

5.33 ± 0.46

4.81 ± 0.28

HPMCAS

<10%

5.99 ± 0.14

10.2 ± 0.28

Soluplus®

10%

11.9 ± 0.60

13.3 ± 2.53

Niclosamide

Celecoxib

Resveratrol
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Table 2.3. Flux values were calculated as a product of initial drug concentration times apparent
permeability coefficient obtained from the studies using Caco-2 monolayers. The initial drug
concentration increased for all ASD formulations, except resveratrol- Soluplus®, with a
concurrent decrease in drug permeability from apical to basolateral compartment. The highest
flux values were observed with niclosamide-PVPVA, celecoxib-DLB2 and resveratrol-DLB3
where significant increases in initial drug concentration compensate for the reduction in
permeability coefficients. The values for initial concentration, Papp and flux are reported as mean
± standard deviation (n=3). C0 (mg/L); Papp (10-6 cm/sec); Flux (x10-8 mg/cm2∙sec); ND: Not
Detectable.
Excipient
API's

Niclosamide

Celecoxib

Resveratrol

Time
None

DLB's

HPMCAS

PVPVA

Soluplus®

C0

1.01 ± 0.02

204 ± 2.14

20.8 ± 0.24

141 ± 1.07

-

Papp

N.D.

0.24 ± 0.01

5.71 ± 0.30

1.58 ± 0.06

-

Flux

N.D.

4.82 ± 0.13

11.9 ± 0.65

22.3 ± 0.73

-

C0

3.66 ± 0.03

252 ± 6.24

34.6 ± 0.54

22.6 ± 0.53

-

Papp

11.6 ± 0.26

1.05 ± 0.02

4.55 ± 0.12

5.17 ± 0.22

-

Flux

4.26 ± 0.10

26.5 ± 0.13

15.7 ± 0.59

11.7 ± 0.26

-

C0

25.8 ± 0.08

176 ± 7.68

156 ± 23.4

-

6.90 ± 0.08

Papp

25.4 ± 0.89

4.81 ± 0.28

10.2 ± 0.28

-

13.3 ± 2.53

Flux

65.3 ± 2.18

84.8 ± 4.32

159 ± 25.8

-

9.17 ± 1.83
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2.4

Discussion
A crystalline peak was not observed in the samples containing Soluplus for up to 4 weeks

storage at 40°C/75% RH. PVPVA was effective in preventing crystallization for all samples except
for resveratrol. The ASD of niclosamide and resveratrol samples contained residual crystallinity
detectable by the PXRD after 4 weeks of storage treatment. There were Bragg peaks presented in
all DLB samples at 2 weeks of storage treatment. Due to the ability to modify the DLB surface
chemistries, the data will be used by Phytoption, LLC to generate novel DLB polymers that could
enhance physical stability. Other characterization and screening techniques are required to better
understand the formation of a single-phase ASD and the potential correlation between drug and
polymer leading to these results. However, these studies will be performed in concert after
additional DLB surface modifications are made in order to increase the ASD physical stability. In
addition, intermolecular interaction between drug and polymeric excipients is proposed to be
investigated using UV-Vis, FTIR and Raman microscopy to detect changes in the molecular
interactions in amorphous dispersion compared to crystalline drug at later stages. Our primary goal
was to investigate the relationship between Solapp and Flux.
To investigate the potential effects of phytoglycogen derivatives on cell viability, the
conversion of MTT to its insoluble formazan derivative by exposed mitochondrial enzymes in
MTT assay was conducted using using Caco-2 cells. At concentrations below 2 g/mL, the viability
of Caco-2 cells remained above 80% for all DLB samples compared to untreated cells in MTT
assay. Incorporation of DLB’s to form amorphous disperison provided the highest flux values for
celecoxib compared to other polymeric excipients, while HPMCAS led to the highest flux value
for niclosamide and resveratrol. The changes in Solapp and the Papp values are discussed in detail
in the following sections.
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2.4.1 The highest initial drug concentration and a concomitant reduction in the Papp value for
niclosamide-DLB1 dispersion
Initial concentrations of niclosamide for the ASD formulations containing HPMCAS,
PVPVA and DLB1 were 20.8, 141 and 204 mg/L, respectively. Niclosamide-DLB1 provided the
highest degree of supersaturation but resulted in the lowest Papp value at 0.24 x10-6 cm/sec (Figure
2.4A). When PVPVA was used as the polymeric excipient, the Papp was 1.58 x10-6 cm/sec. The
highest Papp value of 5.71 x10-6 cm/sec was obtained using niclosamide-HPMCAS which produced
the lowest C0.

Figure 2.4. Changes in the apparent permeability coefficients and flux values for niclosamide
ASD formulations (Panel A) containing (1) HPMCAS at 20.8 mg/L, (2) PVPVA at and (3)
DLB1 at of initial concentration are illustrated. No data was reported for crystalline drug due to
low concentration of drug. The cumulative amount of drug transported from the apical to the
basolateral compartment over a 3-hour period for niclosamide ASD formulations is revealed in
Panel B.

The changes in Papp may be attributed to the differences in the drug release rates from the
polymeric matrix. In this case, the amount of free drug available to permeate through the cell
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barrier may be dictated by the stability of the dispersion and the interactions between drug
molecules and the polymer. It is important to note that all of the experiments for niclosamide
samples were performed with sink conditions and <10% of the donor concentration appeared in
the receiver chamber. The mannitol paracellular permeability (data not shown) and MTT assay
also demonstrated that the cell integrity and viability were maintained, thus this phenomenon is
indicative of the release kinetics. Further work needs to be conducted to accurately delineate the
contributing factors that govern permeability rate changes as a function of time.
2.4.2 The formation of stable drug-polymer colloidal particles and nanoaggregates and a
reduction in Papp
When ASDs are added to an aqueous medium, multiple forms of colloidal particles are
generated, including free drug molecules, solvated polymer units, polymer colloids, amorphous
drug nanoparticles and nanoaggregates (Figure 2.5)42,43. While solid precipitates can be initially
separated via centrifugation, polymer colloids, nanoparticles and a small amount of
nanoaggregates may still be present in the aqueous phase. Absorption only occurs for drug
molecules in the solvated form. The colloidal particles undergo a dynamic process to unload the
drug and replenish them in the bulk solution. This results in prolonged supersaturation and
improved drug absorption. Papp can be calculated based on the appearance rate of drug in the
basolateral side. It accounts for all the diffusional barriers present in the system such as unstirred
water layers (PUWL), collagen coated filter membrane (PC-F) and the cell monolayer (Pm).
1
𝑃𝑎𝑝𝑝

=

1
𝑃𝑈𝑊𝐿

+

1
𝑃𝐶−𝐹

+

1
𝑃𝑚
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Figure 2.5. The illustration depicts the potential dissolution based species that can be generated
from polymeric ASD formulations upon exposure to an aqueous environment in the apical
compartment. Free drug molecules can only be transported into across the epithelial cell barrier
in the solvated form. Other particulate forms can serve as drug reservoirs and replenish the
amount of free drug within the bulk solution.
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When the solubility-enabling formulation is added to the apical compartment, Papp can
change or remain unchanged based on the free drug concentration. The changes become significant
when the release of free drug from the polymeric reservoir is influenced by the erosion of the
polymer matrix, creating a phenomenon that is described as carrier-controlled dissolution (Figure
2.6)44. Amphiphilic polymers consisting of both hydrophilic and hydrophobic components tend to
form a core-shell structure upon contact with water45. The formation of this structural assembly is
rapid due to the thermodynamic stability and the resultant solubility enhancement is associated
with the balance between the preferential hydration intrinsic to the properties of the individual
macromolecules. The term “preferential hydration” is used to describe the physical phenomenon
in which water molecules interact with macromolecules, e.g. protein surface46.

Figure 2.6. In an aqueous environment, polymeric ASD formulation can undergo (A) carriercontrolled dissolution or (B) drug-controlled dissolution. When the excipient is a water-soluble
polymer, the hydration process takes place rapidly resulting in a carrier-controlled dissolution. In
this case, the drug molecules are released at the polymer-water surface in their solvated form.
For drug-controlled dissolution, the polymeric excipient has low water solubility and the drug
molecules are release intact from the matrix.

59
Dendrimer and polymeric micelles, can form nano- and microstructures in solution and can
act as colloidal drug carriers, provided the drug interactions are competitively strong enough in
comparison to water47. Briefly, dendrimer polymeric micelles have increased drug loading
capacity due to the hydrophobic core structure and high dispersion stability based on the presence
of the hydrophilic chains. Combined with other factors including hydration level and polymer
swelling capability, dendrimers contribute to the solvation and stability of the drug-polymer
system in the aqueous environment48. If the ASD formulation gives rise to the colloidal particles
resembling the core-shell structure, the carrier-controlled dissolution can take place, and the
diffusion of drug across the polymeric matrix into the bulk solution can be defined using the
Stokes-Einstein below. We must note that the use of the Stokes-Einstein equation infers our
assumption that assemblies are spherical in nature. The diffusion coefficient is denoted by D. It is
proportional to the temperature (T) and inversely proportional to the viscosity (ƞ) and
hydrodynamic radius of the particle (R). Here, k is the Boltzmann constant.
𝐷=

𝑘𝑇
6𝜋𝜂𝑅

It has been suggested that the polymeric excipient and drug molecules may form molecular
interactions that are highly favorable. These interactions lead to the formation of a stable drugpolymer system in water that can influence the drug release mechanism49. In the carrier-controlled
dissolution process, the release of free drug into apical compartment or intestinal lumen is
controlled by the activity or chemical potential of undissolved solute. Under certain circumstances,
such as highly exothermic mixing of drug and polymer, thermodynamic driving force becomes
negative and the chemical potential of ASD may fall below the crystalline form of drug50. ASD
formulations have been proven to be one of the most effective solubility enabling formulations,
but the ultimate success can only be realized when the system has been optimized for (1)
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amorphization or formation of ASD, (2) storage stability during a pharmaceutically relevant time
frame, and (3) solubilization enhancement in an aqueous environment17. A well-balanced
interaction between drug and polymeric excipient is of crucial importance for successful outcomes
of ASD formulations.
2.4.3 Inverse proportionality between initial drug concentration and Papp across Caco-2 cell
monolayers
Flux is defined by the initial concentration multiplied by the permeability coefficient.
Solubility enabling formulations such as ASDs should lead to an increase in flux based on
concomitant increases in both initial apparent free concentration and permeability51. In contrast, a
decrease in the Papp was observed for the niclosamide-DLB1 dispersion. A similar pattern in which
increase in drug supersaturation was associated with a decrease in apparent permeability
coefficient was found in all three drugs tested. For celecoxib-DLB2 and resveratrol-DLB3, the Papp
of the drug decreased from 11.6 to 1.05 x10-6 cm/sec (p<0.0001) and 25.4 to 4.81 x10-6 cm/sec
(p<0.0001), respectively, compared to the sample containing crystalline drugs (Table 2.3).
The addition of PVPVA provided a 13-fold increase in Solapp of niclosamide. Although the
concentration of niclosamide-PVPVA sample was 30% lower (p<0.0001) than that of the sample
containing DLB1, it exhibited a Papp that is approximately 6 times higher (p<0.0005).
Consequently, the flux value of the sample containing PVPVA was highest. Niclosamide-PVPVA
also led to the highest amount of drug transported from apical to the basolateral compartment after
3 hours.
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Figure 2.7. Changes in apparent permeability coefficient and flux for celecoxib (Panel A) and
resveratrol (Panel C) ASD formulations. The cumulative amount of drug transported from the
apical to the basolateral compartment over a 3-hour period for pure drug and polymeric
dispersions of celecoxib (Panel B) and resveratrol (Panel D).

A similar pattern was observed for the ASD’s of celecoxib (Figure 2.7A). The
incorporation of HPMCAS resulted in a slight increase in the Solapp (p<0.05) of celecoxib and a
similar Papp compared to the formulation containing PVPVA, thus the sample containing
HPMCAS resulted in a slightly higher value of flux (P<0.0001). The permeability of the drug
decreased from 11.6 x10-6 to 1.05 x10-6 cm/sec (p<0.0001) when the celecoxib-DLB2 dispersion
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was added to the donor compartment, but this sample was found to have the highest flux value due
to its large magnitude of concentration increase compared to crystalline drug (252 versus 3.66
mg/L, p<0.0001)).
In the case of resveratrol (Figure 2.7C), both DLB3 and HPMCAS resulted in a large increase in
Solapp and up to approximately 80% decrease in Papp for resveratrol-DLB3 versus crystalline drug
sample. However, the solubilization capacity also resulted in a significant increase in the flux from
65.3 x10-8 mg/cm2∙sec for crystalline drug sample without polymer to 159 x10-8 mg/cm2∙sec
(p<0.0005) with resveratrol-HPMCAS. Moreover, samples prepared from resveratrol-Soluplus®
dispersion had a drug concentration lower than the reported solubility of resveratrol alone in its
crystalline form and a lower Papp leading to the lowest flux value of 9.17 x10-8 mg/cm2∙sec.
2.4.4 A large increase in initial drug concentration compensates for the reduction of Papp
The samples prepared from amorphous dispersion using DLB1 resulted in a decrease in
the flux of niclosamide across Caco-2 cell monolayers. The flux of celecoxib and resveratrol
formulated with DLBs were, however at the highest values compared to other formulations
containing other excipients and drug alone. In these cases, the amorphous dispersion provided a
significant increase in the Solapp that enhanced the flux values. Although there were reductions in
the values for the Papp, the samples containing DLB2 resulted in highest values of flux for celecoxib.
The celecoxib-DLB2 dispersion induced a significant increase in the supersaturation level and
made up for the reduction in Papp. For niclosamide, however, the highest flux was achieved with
addition of PVPVA in the ASD formulation. The flux value for niclosamide-PVPVA was 22.3 x
10-8 mg/cm2∙sec which is 2 times (p<0.0001) and 5 times (p<0.0001) higher than that of ASD
containing HPMCAS and DLB1, respectively. Although DLB1 added to the formulation resulted
in the greatest supersaturation level, it was insufficient in compensating for a sharp decrease in
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permeability coefficient of niclosamide caused by the DLB1-drug binding interactions leading to
reduced free compound solubility. For resveratrol, DLB3 and HPMCAS provided a similar
increase in Solapp, but resveratrol-DLB3 has a lower Papp and thus a flux value that is lower than
the resveratrol-HPMCAS (p<0.001) and similar to crystalline drug sample was obtained.
According to a literature assessment consisting of 40 research papers, amorphous dispersions
led to improved bioavailability in 82% of the cases38. This suggests that ASD can be an effective
method for improving the performance of poorly water soluble drugs. However, a knowledge gap
still exists for in vitro and in vivo relationships in this area, which may be the underlying cause for
unchanged or decreased bioavailability in other cases. The development and in vitro evaluation of
ASD are performed based upon dissolution testing and focus on the increase in solubility and
achieving the “spring-and–parachute” effect52. While this approach is an essential characteristic of
ASD for obtaining prolonged supersaturation, its effect on absorption in an in vivo environment
may be precluded due to the presence of other confounding factors (e.g. absorptive surface,
dynamic exchange of dissolution species, intestinal precipitation, luminal contents, differences in
fluid distribution in the intestine, etc.)53–55. Bevernage et al conducted an experiment using Caco2 cultured on Transwell® inserts to investigate supersaturation in an absorptive environment56. The
results showed that the optimal degree of supersaturation based on formulation performance in a
non-absorptive condition did not correlate with the highest transport in an absorptive surface. Thus,
the Caco-2 permeability assay may provide additional insight to augment the evaluation of the
ASD performance in vitro.
The effects of solubility-permeability interplay on drug transport across a membrane barrier
have been associated with solubility enabling formulation. The trade-off between these two
parameters can be observed regardless of the solubility enhancing mechanism. The magnitude of
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changes can be attributed to the interaction between drug and excipient, which is inversely
proportional to the availability of drug within the aqueous environment. A well-balanced
interaction is required to achieve a supersaturation and a clinically relevant supersaturation.
Additionally, the interaction needs to be maintained over time to avoid the precipitation of the drug
in the donor compartment or the intestinal lumen prior to the transport of drug across the intestinal
barrier. Further improvement on DLBs can be made to develop excipient that can be used for ASD
formulation for niclosamide and the other two drugs. Other studies such as DSC, ITC, drug release
assays and biphasic dissolution systems can be conducted to collect additional data that can be
used as a guide in the further optimization of DLB excipients. Moreover, the DLB properties
enable tailoring of the surface chemistry to better stabilize and control release rates from an ASD
formulation.

2.5

Conclusions
DLBs can be used to prepare ASD formulation for niclosamide, celecoxib and resveratrol.

A low level of crystallization occurred in the celecoxib- DLB2 formulation at 2 weeks (40˚C/75%
RH) with little to no changes in the PXRD pattern after 4 weeks. However, there was a significant
development of Bragg peaks indicating crystallization for DLB1 formulated niclosamide and
resveratrol. The permeability studies using Caco-2 cell monolayers showed that there is a
reduction in the apparent permeability of drug formulated as ASD with polymeric matrix that leads
to the increased Solapp, but not free drug in solution. The reduction level may be related to the
interaction between the drug molecules and the polymer. A significant decrease in the Papp values
led to a reduction in flux for nilcosamide-DLB1 compared to the formulation containing PVPVA.
The changes in Papp may be attributed to the differences in the drug release rates from the polymeric
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matrix. While the biopolymers were found to be less effective in preventing crystallization of the
amorphous materials compared to other commercialized polymers, DLB2 provided the highest
increase in flux among all three formulations of celecoxib. Furthermore, the evaluation of the DLB
polymers here was to evaluate the potential for an impact on performance, as implicated by flux.
Since the DLB polymers can be readily surface modified through functionalization, the next
generations of the polymers should focus on reducing nucleation potential, increasing carrying
capacity, and provide higher flux values in in vitro screens prior to advancement. Therefore, the
evaluation here should serve as a guidance for the further improvement on DLBs to tailor their
potential to be used for ASD formulation of niclosamide, celecoxib and resveratrol. Such an
approach should also be encouraged for the development of other compounds using DLB
excipients for the development of physically stable and enhanced ASD formation with improved
performance in the future.
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LIMITING THE EXPEDITED PRECLINICAL TO CLINICAL
TRANSLATION IN CHILDREN

Modified From: Lavan M, Byrn SR, Knipp GT.
Pediatric Formulations: Knowledge Gaps Limiting the Expedited Preclinical to Clinical
Translation in Children.
(In Preparation)

3.1

Current Status
Traditionally, a majority of drug discovery and development research has been focused on

the mitigation of disease treatment for the general adult population, often overlooking the medical
needs in pediatric patients. While remarkable progress toward the discovery of better medicines
and formulations have been made, the pharmacological and pharmacodynamic differences
between children and adults are often neglected as part of the translation process1,2. In fact, until
recently children have been considered therapeutic orphans due to the lack of significant discovery,
formulation development and dosage form design specifically tailored for pediatric patients3.
Perhaps the least understood is the significant physiological changes that occur during the
maturation process from birth to adulthood, which requires significant consideration to achieve
age-specific desired therapeutic outcomes with minimal toxicity4,5. This introduces considerable
risk into the preclinical and clinical testing of new medicaments, which until recently was avoided
based on the stipulation that safe use in adults would help minimize the chance of adverse juvenile
responses. Thus, the lack of appropriate drug products for children have led to off-label use of
adult medicines with potential life-threatening adverse reactions and health complications6,7.
Recent developments and future considerations regarding pediatric drug discovery and

72
development using a patient-centric approach in the context of ontogenic biopharmaceutical
considerations are discussed below.
Given the traditional view and our lack of knowledge on drug discovery and development
for pediatric populations, there has been a concerted focus on improving therapeutic outcomes
through incentivizing pharmaceutical companies to investigate the use of drug products in children.
The World Health Organization (WHO) and international regulatory agencies have worked to raise
awareness and promote pediatric research activities in both academic and industrial settings8. The
Best Pharmaceutical for Children Act (BPCA) was established by the Food and Drug
Administration (FDA) to provide an additional six months of market exclusivity for drug products
that have been clinically evaluated in pediatric patients. The Pediatric Research Equity Act (PREA)
is another legislation that requires the pediatric clinical assessments to be conducted by the
pharmaceutical companies, unless there is a strong justification for bypassing testing, e.g. aging
based disorders. The enactment of BPCA and PREA and other regulatory changes have been
proven to be effective based on the increase in the number of pediatric drug labeling in recent
years. The regulatory changes have proven to be effective based on the increase in the number of
pediatric drug labeling in recent years9,10. Similarly, the European Medicines Agency (EMA) also
enforced the integration of pediatric studies at an early stage of drug development. In addition to
regulation enforcement, working groups were formed with representatives from academic,
industrial and governmental institutes to identify major issues in pediatric drug development and
determine appropriate solutions11. One critical gap was identified across the board to further
facilitate pediatric drug discovery and development is to establish the ontogenic based changes
during the different stages of growth and their relevance in guiding new and repurposed
formulation development.
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3.2

Challenges in Pediatric Drug Formulation
Rapid development occurs from birth to adulthood creating a spectrum of physiological

conditions in pediatric population12. This leads to further classification of multiple subgroups at
different stages of maturity, namely neonates (0 – 27 days), infants (28 days – 23 months), children
(2 – 11 years) and adolescent (12 – 18 years). Despite the apparent differences between multiple
pediatric subgroups, the ontogeny-driven effects are often not delineated or well examined in
clinical trials. For example, a large variability in the age of patients was found in the pediatric
studies published by the Cochrane Central Register of Controlled Trials (CENTRAL) during the
year of 2007, but an age-group analysis was performed in only 25% of the studies13. This may be
due to the limited availability of participants enrolling in pediatric clinical trials, however, there
does need to be increasing awareness of the importance of striation placed in the field.
Extrapolation of data from pediatric clinical trials to guide drug development is also confounded
by the fact that, to our knowledge, there has never been a clinical trial conducted in a healthy
childhood population. In part this arises from safety considerations regarding exposing children to
unpredictable risks. In an attempt to overcome these ethical issues, changes in current regulations
have created a paradigm shift in the public point of view from “protecting children from research”
to “protecting children through research”14,15.
In addition to the changes in clinical responses for the active pharmaceutical ingredient (API),
the effects of excipients added in the formulation must also be considered16–18. Several studies
have suggested that acceptable excipients levels used in adult formulations have been suggested
to be toxic in children at the same concentration. For example, benzyl alcohol is an excipient that
is commonly used as a preservative, has been suggested to be causative of gasping syndromes in
neonates19. The side effects of neonatal exposure to high levels of benzyl alcohol are severe and
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include neurological deterioration, contribution to organ failures, metabolic dysfunction and
respiratory distress. In 2011, a safety labeling change was required for the presence of ethanol and
propylene glycol, at a relevant amount in the Kaletra® formulation of anti-HIV drug combination
of lopinavir/ritonavir, due to excipient toxicity reported in newborns20. Several other cases have
been reported and resulted in a need to collect additional toxicity data for excipients in children.
In response to these toxicity issues resulting from excipient use in pediatric drug formulation, the
Safety and Toxicity of Excipients for Pediatrics (STEP) database was created to provide access to
information on excipient usage for children21–23.
Another key concern is the lack of safety and efficacy oriented preclinical animal models
used to assess the pharmacokinetic (PK) and pharmacodynamic (PD) in drug development process,
which have yet to be established for pediatric research15,24. There are many cases where the
traditional animal models have been demonstrated to not be adequate for predicting adult PK/PD,
thus suitable pediatric models would be even harder to establish. Differences in drug absorption,
distribution, metabolism, excretion and toxicity (ADMET) should be incorporated in animal
studies to help determine the potential changes in the age groups and the potential implications on
dosage tailoring for a dynamic safe and efficacious dose range. Absorption is one key aspect as
the rate of absorption needs to balance disposition driving ontogenic changes in order to ensure a
safe and efficacious response. For pediatric oncology patients, the failure to understand the rate
determining mechanisms of dosage form performance that effects absorption is also predicated on
a more comprehensive understanding of the ontogenic changes in gastrointestinal transporter and
enzyme expression. Without the fundamental background knowledge across species and the
relationship to pediatric to adult populations, the knowledge gaps may significantly limit the ability
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of the therapeutic agent to reach systemic exposure and has been theorized to be one of the main
causes of high attrition rate in the development of drugs such as anticancer agents25–27.
Another significant factor is that chronic illnesses are less frequent in pediatric patients, thus
the population size is smaller and underrepresented in clinical studies. The lack of clinical
knowledge, albeit in diseased children, presents an inordinate increase in safety concerns
comparative to adults28–30. The disparity in pediatric clinical results further justifies the necessity
of validating clinically relevant animal models that can accurately predict risk and potentially
efficacy. This is further justified by the fact that many age-related effects on disease characteristics
and drug responses have also been observed in children, where preemptive screening may have
minimized these unintended outcomes31–33. In this regard, the physiological barriers associated
with in vivo models may better mimic the systemic changes across pediatric age ranges that would
not be adequately reflected in studies using current in vitro and more established adult in vivo
animal models. The use of preclinical models for pediatric drug development is further discussed
in the following section.
3.2.1 Lack of Appropriate Preclinical Assessments
The translation of hits to leads almost universally begins in rodents (mice and rats primarily),
which are the most studied preclinical models34,35. However, the difference in their developmental
physiology from humans is a major disadvantage, particularly in areas like organogenesis36. This
is particularly important for pediatric drug development, which requires similar body maturation
rate to assess its impact on ADMET. The life span of mice and rats are also shorter, and therefore
extended pediatric therapeutic toxicity is not easily obtained using these traditional early toxicity
screening models.
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There have been a number of studies contrasting the utility of larger animal models due to
translational advantages allowing extensive analyses that are not possible in small animals37,38.
One model of interest for our laboratory has been the swine (porcine) model, which has been
utilized for drug studies in pediatric populations39–41. The porcine model shares several similarities
with humans with respect to anatomical, physiological and biochemical properties, making them
suitable for pediatric pharmacokinetic studies42. For example, the Jaeger laboratory has
demonstrated that developmental maturation in the porcine intestine parallels humans and is
completed by parturition, whereas the rat intestine still matures into infancy43,44. In fact, several
studies have also suggested that the porcine model is the best large animal model for studying
digestive diseases and superior to rodent models37,45–47. Swine models for cancer studies have also
been established using various technologies including targeted gene editings48–50.
Domesticated swine weighing up to 50 kg have been used in research studies in our
laboratories, and miniature pigs have also been utilized in preclinical testing because they are easy
to handle51. In a comparative PK study of glipizide, pig and dog models were used for immediate
and modified release formulations52. For the 10 mg modified release formulation, pigs showed a
more consistent exposure with a coefficient of variance of 54% which was lower compared to dogs
(80%). The absorption PK parameters and bioavailability value obtained in pigs more closely
resembled the data reported for humans.
Juvenile porcine models were assessed for their potential to serve in preclinical
pharmacokinetic testing as human pediatric surrogate53. Juvenile (20 kg) and adult pigs (40 kg)
were administered with rifampin in capsule form at an equivalent dose of 14.5 – 14.7 mg/kg as
recommended by WHO53. A lower level of exposure was observed for juvenile pigs with an AUC
value of 58.1 µg h/mL comparing to 188.4 µg h/mL in adult animals. The ontogeny-related
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changes between the two groups was also seen in the maximum plasma concentration (Cmax),
which is lower in juvenile pigs (7.0 versus 28.8 µg/kg) while the Tmax values were the same (2.0
h). Both the Cmax and Tmax values from juvenile porcine models fell within the range reported
for pediatric humans in literature after dose normalization was applied in the comparison. In a
separate study in our laboratory, an oral buccal film strip formulation containing a measles vaccine
was tested to assess if it would elicit a systemic immune response in juvenile pigs54. The results
of these studies revealed that antibody titers, as determined by ELISA, against the vaccine where
visible after the initial administration and increased with additional dosing.
3.2.2 Innovative Oral Dosage Form for Pediatric Medicines
Many innovative approaches that have been studied for the general adult population does
not focus on overcoming the challenges in pediatric drug administration, which is often associated
with swallowing difficulty, mouth-feel and taste preferences. In term of oral administration, minitablets, granules and pellets have been proven to be the most acceptable solid dosage forms for
pediatric patients55–57. Liquid formulations such as syrup have been commonly used for children,
but stability and drug loading may be an issue rendering its application for a wide range of API’s.
On the other hand, mini-tablet have gained increasing interests because it can provide ease of
administration and dose flexibility similar to oral liquid dosage form. In addition, improved
stability, high drug loading and reduced transportation cost can also be achieved with the use of
mini-tablets.
Several studies demonstrated the suitability of mini-tablets for pediatric age groups
including infants and neonates58–60. A higher acceptability of mini-tablets compared to liquid
formulation was observed for children from 6 months to 6 years of age61. In neonates, the
acceptability of mini-tablets was similar to syrup with an even higher swallowability62. Food
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particle size distribution ranges from 0.82 to 3.04 mm, according to studies conducted on
mastication, prompting the FDA to recommend the target bead size of drug products that are
labeled for administration by sprinkling to be at 2.5 mm maximum63–65.

Figure 3.1. Display of mini-tablet (red arrow), ice cream sprinkles, a conventional tablet
(Tylenol®) and United States one-cent coin for size comparison.
3.3

Effects of Ontogeny on Pharmacokinetic

3.3.1 Gastric Conditions
The gastric volume is over five folds smaller during infancy compared to adulthood66. The
final concentration of the drug should be taken into consideration, especially for oral liquid dosage
forms, due to limited functional volume in the stomach. Feeding frequency and tendency for
gastric reflux can also affect the delivery of the drug. In fasted state, a similarity between gastric
volumes of children and adult was obtained with weight normalization. Gastric emptying is
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prolonged and the time to reach maximum drug plasma concentration is longer in neonates. An
increasing trend in the drug absorption rate of phenobarbital, sulfonamides and digoxin was found
in pediatric patients from 3 weeks to 1 year old.67 The secretion of gastric acid is low, thus creating
a neutral pH environment in the stomach of neonates. This can influent the pH-dependent solubility
and availability of acid-labile drugs.

Figure 3.2. This is an illustration that summarizes the physiological changes occurring from birth
to adulthood leading to potential alteration in drug absorption and disposition. Adapted from
Kearns et al. 200312.
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3.3.2 Intestinal Barriers
The functional surface area of the small intestine undergoes an increase of over 40-folds
during human development. The intestinal mobility does not differ between children and adults
when tested with the same method, and the pH level is also not affected by age. In addition to
physical and mechanical barriers, the absorption of the drug is subjected to biochemical processes
in the small intestine. The expression of multidrug resistant protein 1 (MDR1), also known as pglycoprotein (P-gp), was found to be lower in neonates, while the organic anion transporting
polypeptide (OATP)2B1 is highly expressed in this age group68,69.
Intestinal transporters and enzymes play an important role in the patient’s response to drug
treatment70. Cytochrome P450 refers to a superfamily of enzymes present in the hepatocytes and
at a lesser extent in the enterocytes.71 The expression of cytochrome P4503A (CYP3A) subfamily
was confirmed at up to 80% in the small intestine72. In a study using Western blotting and
immunohistochemistry, the expression level of duodenal CYP3A4 was found to be significantly
lower in neonates73. The CYP3A4 enzyme residing in the gut wall is responsible for a significant
reduction in oral bioavailability of some compounds during first-pass metabolism74,75. Docetaxel,
tacrolimus and sirolimus are known to be susceptible to intestinal CYP3A drug metabolism. The
effects of age on the ratio of the metabolites (i.e. 16-O-demethylsirolimus and 24hydroxysirolimus) to sirolimus was observed in a clinical trial with patients having
neurofibromatosis76. Genetically modified mouse models showed a dramatic decrease in the drug
absorption for docetaxel when tissue-specific expression of CYP3A4 was introduced in the small
intestine compared to the liver77. It has been proposed that the overlap in substrate specificity of
CPY3A enzymes and MDR1 transporter may be the cause of unexpectedly high intestinal firstpass metabolism that occur in a synergistic manner75,78,79. When tacrolimus was given to pediatric
patients after a heart transplant, a higher amount of drug was required in CYP3A5 expressers to

81
obtain the same blood concentration as the nonexpressers80. A similar situation was also seen for
different genotypes of MDR1 (i.e. G2677T versus C3435T) at 6 and 12 months but not during the
earlier post-transplantation period.
3.3.3 Age-Related Changes in Drug Distribution
Dramatic changes in body composition occur during rapid growth and maturation. Total
body water and extracellular water decrease and reach a stable level after the age of 1-year old,
which can result in a decrease in plasma concentration of hydrophilic drugs81. While total body fat
decreases in children as they progress into adulthood, the contents (lipid and water composition)
of adipose tissues are different in neonates compared to adults. Lipid content was 40% in neonates
and increases with age to 75%82. The plasma concentration of albumin and α1-acid glycoprotein
remains below the adult’s level for the first year after birth83. Administration of highly plasma
bound drugs at a standard dose can put neonates at risk due to a higher fraction of free drug in the
systemic circulation. Diazepam and cyclosporine had a 3 to 4-fold higher of unbound fraction in
children versus adults.84 When deltamethrin was given in the same study, the unbound fraction
was higher only during neonatal period at 0 to 1 month.
In hepatic metabolism, CYP3A4 enzyme has an opposite pattern of expression with
CYP3A7 which is influenced by the maturation process85. Newborns treated with sildenafil for
persistent pulmonary hypertension had a 3-fold increase in clearance from day 1 to day 7 after
birth86. Due to immature metabolic capability of CYP3A4 in neonates, potential side effects can
occur when drugs primarily metabolized by this enzyme are used. For example, cisapride caused
side effects when administered in neonates with nonfunctional CYP3A4 enzymes87. In 2000, the
drug was withdrawn from the market dues to reported serious cardiac adverse event. It was later
confirmed that cisapride does not get broken down by CYP3A5 and CYP3A7 that are often
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expressed at a higher level during neonatal period before the transition takes place88,89. The rapid
maturation of enzymatic expression in the early stage of life makes it difficult to predict the
pharmacokinetic parameters of the pediatric population based on individual levels. Leeder and
Kearns demonstrated the changes in the activity of CYP2C19, which the authors referred to as a
“moving target” due to the challenge associated with the variation in drug disposition and response
in pediatric patients90. The ontogeny related effects on enzymatic expression in pediatric patients
versus adults have are well defined in multiple sources in literature91–93. It should be noted that the
variation in level of enzyme expression within the same age group may also exist, similar to the
cases in adult patients94. Multiple factors such as genetic heredity, diet, environment and health
conditions may also play a role in the individual expression level of transporter and enzymes95,96

3.4

Conclusions
In order to make better pediatric medicines and meet the high demand in this population,

further research needs to be conducted to understand the physiological conditions in pediatric
patients affecting clinical outcomes and toxicity. Innovative dosage forms such as mini-tablets and
other oral dispersible formulations should be investigated, in addition to liquid forms, to facilitate
dose flexibility and patient adherence, which are common challenge in pediatric drug
administration. Incorporation of ontogeny-related changes in preclinical testing should be done,
and the differences in patient necessities between different subgroups need to be considered to
provide patient-centric medicines for pediatric patients.
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DEVELOPMENT OF A PEDIATRIC MINI-TABLET
FORMULATION FOR EXPEDITED PRECLINICAL STUDIES

Modified From: Lavan M, Wang X, McCain RR, Jannasch AS, Cooper BR, Byrn SR, Knipp GT.
Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies.
(In Preparation)

4.1

Introduction
Pediatric drug development requires extensive knowledge on physiological properties and

medical needs that are different from adult patients. Body composition, transporter activities,
enzymatic expression, and consequently absorption and disposition undergo rapid changes from
birth to maturity1,2. These changes can directly impact drug absorption, distribution, metabolism,
excretion and toxicity (ADMET), and result in adverse responses3–5. For example the
administration of chloramphenicol to neonates, at a dose extrapolated from the therapeutic level
used in adults, triggered a set of symptoms identified as gray baby syndrome6,7. This condition is
caused by accumulation of drug due to the low expression of UDP glucuronosyltransferase
enzymes at early stages of development8. In addition, excipients used in the drug formulation at
an acceptable level for adults can also elicit adverse effects in children9,10. The relevant amounts
of propylene glycol and ethanol present in the formulation of lopinavir/ritonavir (Kaletra ®)
required a safety labeling change after toxicity cases were reported in newborn infants11. The lack
of research studies and drug products specifically designed for children has resulted in numerous
unpredicted therapeutic responses.
Currently, a significant majority of the treatments provided for pediatric patients are drugs
that have been approved and prescribed for adults, and often given to children after prolonged use
in elder patients. Moreover, medicaments without appropriate pediatric labeling are often prepared
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extemporaneously by breaking compromising the adult dosage form (e.g., grinding a tablet) to
disperse in vehicles that results in variable dosages despite enabling drug administration in young
children that have swallowing difficulty. Over the years, extemporaneous preparations are
increasingly being highly discouraged because they can interfere with the properties of the drug
product and produce unwanted side effects12. The inadequacy of pediatric medicines has led the
regulatory agencies, including the Food and Drug Administration (FDA) and European Medicines
Agency (EMA) to take actions9,13. In 2002, the FDA established the Best Pharmaceutical for
Children Act (BPCA) to grant a six-month market exclusivity for drugs that have been assessed
for pediatric applications. The Pediatric Research Equity Act (PREA) is another legislation
introduced in 2003 to mandate pediatric studies in the development process of drug and biological
products. A significant increase in the number of drug assessments for children and the number of
pediatric patients enrolled in clinical trials were evident under the implementation of BPCA and
PREA14.
The Safety and Toxicity of Excipients for Pediatrics (STEP) database is being developed, in
its pilot version, as part of a collaborative effort from the European and United States Pediatric
Formulation Initiatives (Eu-US FPIs). This database stores information on excipient usage and
safety collected from studies performed at various ages, most of which have limited to no concerns
for adult usages15,16. Further research is necessary to incorporate the pediatric assessment as a
permanent part of drug development and meet the high demand for pediatric medicines. It is clear
that effective pharmacotherapeutic dosage forms for children need to be appropriately designed
with acceptable excipients in mind to provide formulations offering better patient adherence and
age-based dose flexibility.
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Allometric dose scaling from adult to pediatric patients does not account for the changes in
pharmacokinetic (PK) and pharmacodynamic (PD) of drugs17. The effects of ontogeny on clinical
outcomes and toxicity need to be assessed for different pediatric subgroups. Furthermore, the lack
of preclinical models creates persistent challenges in the study and design of pharmacotherapy for
pediatric patients. Porcine models have been illustrated to share many physiological similarities
with humans in terms of gastrointestinal system and drug metabolism making them a suitable
model in preclinical tests preceding clinical studies18,19. Achour et al. demonstrated that pig
CYP3A29 and CY3A39 were equivalent to human CYP3A4/5 with a sequence similarity of 87%
for both enzymes using label-free proteomic methods20. Several cytochrome P450 isoforms,
aldehyde oxidase and N-acetyltransferases were found to be expressed in pigs but not dogs, which
is one of the primary preclinical model commonly used in drug studies21. A comparative PK
analysis using pig and dog models were performed for immediate and modified release
formulations of glipizide22. A consistency was observed between the absorption kinetics and
bioavailability of the glipizide modified-release formulation in pigs, compared to the published
clinical data for humans.
Roth et al. conducted PK testing of rifampin using juvenile and adult pigs23. Significant
similarities in the PK parameters between juvenile pigs and pediatric patients were found for
rifampin in a dose-normalized comparison. Moreover, there was an ontogenic difference observed
between the juvenile and adult pig models that were statistically similar to literature reported
values for corresponding age range human patients. Juvenile porcine models can facilitate
translational research because of the similarities in their development to that of pediatric humans,
unlike small preclinical models such as rodents that have shorter life spans and different growth
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rates. Predictive preclinical models with the incorporation of the ontogeny-related effects play an
important role in the pediatric drug development process.
Dose flexibility can mitigate toxicity issues and optimize therapeutic outcomes by providing
adjustable amounts of drug to accommodate ontogenic based changes in PK/PD depending on the
developmental stage of the patient. Hence, multi-particulate dosage forms such as mini-tablets
have gained increasing interest in recent years due to ease of administration and dose flexibility,
which are common challenges for pediatric medicines24–28. In 2012, the FDA recommended a
maximum target bead size of 2.5 mm for drug products labeled as sprinkle29. This is based on
multiple individually conducted studies, which revealed that food particle size distribution ranges
from 0.82 to 3.04 mm after chewing and prior to swallowing30,31. Oral administration of
conventional tablets can cause dysphagia in children with undeveloped organs, sensory function
and motor coordination32,33. Dysphagia can occur at all ages but with a higher risk in pediatric and
geriatric populations as well as individuals with certain medical conditions such as stroke and
respiratory issues34,35.
Mini-tablets are generally equal to or less than 3.0 mm in diameter, making them more
suitable for oral administration of drug in patients with dysphagia. The acceptability of mini-tablet,
2 mm in diameter, was greater than syrup when tested in a randomized controlled trial with sixmonths to six years-old subjects36,37. A similar study conducted in neonates aged 2 to 28 days also
showed that mini-tablet was more favorable compared to syrup38. In addition, mini-tablets can
enable flexible-dose trials to be performed for preclinical and clinical research. Unlike a fixeddose trial, in which the subjects are given the same level of drug regardless of their tolerability,
suboptimal dose can be achieved in a trail with a flexible dosing system39. The dose flexibility can
be beneficial in clinical settings for drugs with a narrow therapeutic index and antidepressant
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medications in which the dosage need to be adjusted based on the patient’s responses19. In pediatric
drug development, mini-tablets can be used to increase patient adherence and to optimize
therapeutic outcomes.
Pediatric population, especially newborns, are vulnerable to various infectious diseases and
other health problems40. According to the National Vital Statistics Reports provided by the Center
of Disease Control and Prevention (CDC) in 2014, cancer was a leading cause of death in both
adults and children. The survival rate of childhood cancers is very low creating more deaths than
HIV infections, tuberculosis and malaria combined41. Leukemia and Central Nervous System
(CNS) tumors are the most commonly diagnosed cancer cases in pediatric patients42,43. The
pathogenesis studies in cancers revealed that there was a high level of human epidermal growth
factor receptors (EGFR), also known as HER1, and HER2 being expressed in various childhood
brain tumors. Immunochemical studies in children with medulloblastomas showed a 70% rate of
HER2-positive, making them the potential target for cancer therapies44. EGFR and HER2
expressions were found to be associated with advanced cancer cases in both adult and pediatric
populations45–47. In 2005, lapatinib ditosylate (Tykerb®) was approved by the FDA for the
treatment of breast cancers in women with overexpression of HER2 receptors, which is often
associated with increased risk of disease progression and death48. Lapatinib acts as an anticancer
agent by blocking the ATP-binding site of intracellular tyrosine kinase receptors, that function in
the signal transduction pathway, leading to rapid cell division in tumors49. Tyrosine kinase
inhibitors have been studied for their potential as targeted therapies in pediatric cancers50,51. Most
of these compounds, however, are limited by low solubility in an aqueous environment and poor
oral bioavailability52.
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Polymeric amorphous solid dispersion (ASD) has been shown to be an effective approach
for solubility enhancement of orally administered drugs53,54. The increased solubility associated
with the amorphous form can only be achieved when the physical stability is maintained during
manufacturing and storage. The amorphous material undergoes crystallization to form the
thermodynamically stable crystalline form. Polymeric excipients are commonly used to inhibit
crystallization and obtain a stable ASD formulation. Song et al. demonstrated that acidic polymers
such as hydroxypropyl methylcellulose phthalate (HPMCP) and hydroxypropyl methylcellulose
acetate succinate (HPMCAS) exhibited ionic interactions observed using Differential Scanning
Calorimeter (DSC) and solid-state Nuclear Magnetic Resonance (ssNMR)55. A discrepancy
between the calculated and experimentally measured glass transition temperature (Tg) of lapatinibHPMCP was indicative of the intermolecular interaction formed between the drug and the polymer.
The ionic formation between lapatinib and HPMCP was also confirmed using 14N NMR, which
showed a peak corresponding to the ionized amino group, in addition to the peak of unionized
amine nitrogen found in pure lapatinib sample. The drug-polymer intermolecular interaction of
lapatinib-HPMCP was further delineated using synchrotron x-ray diffraction and pair distribution
function analysis (PDF)25. Lapatinib ASD formulated with HPMCP and hydroxypropyl
methylcellulose E3 (HPMCE3) were found to exhibit distinct nearest neighbor contacts with the
total PDF x-ray pattern. This suggests that there was a difference in drug clustering within the two
ASD systems due to the lack of acid-base interaction for lapatinib-HPMCE3. Molecular
interactions occur between the drug and the polymer can lead to the formation of an amorphous
dispersion with increased apparent solubility (Solapp) and storage stability56,57.
The objective of this study is to incorporate multiple aspects of pediatric drug development
for lapatinib ASD mini-tablet formulation and create a platform for expedited preclinical studies
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using juvenile porcine models. First, ASDs of lapatinib were prepared using two different
polymeric excipients, namely HPMCP and HPMCE3, to achieve an increase in Solapp of the drug.
Mini-tablets, 2 mm in diameter, were manufactured using rotary tablet press with formulations
containing the two amorphous dispersions and varying levels of croscarmellose sodium (CCS) as
the disintegrant. The mini-tablets were characterized based on tensile strength, percent friability,
content uniformity, disintegration and dissolution. Finally, juvenile pigs at 10 and 20 kg were used
as preclinical models to investigate the effect of ontogeny on PK parameters of lapatinib.

4.2

Materials and Methods

4.2.1 Materials
Lapatinib was purchased from Attix Pharmaceuticals (Ontario, Canada). HPMCE3
(METHOCEL™ E3 Premium LV) was obtained from Dow Chemical Company (Midland, MI,
USA). HPMCP was donated by SE Tylose (Plaquemine, LA, USA). Microcrystalline cellulose
(Avicel® PH 200) and CCS (Ac-Di-Sol®) were obtained from FMC BioPolymer (Philadelphia, PA,
USA). Magnesium stearate was obtained from Mallinckrodt (Surrey, UK). Colloidal silicon
dioxide, methylene chloride, methanol, and acetonitrile and all other supplies were purchased from
Fisher Scientific (Waltham, MA, USA).
4.2.2 Preparation of Lapatinib Polymeric ASD
HPMCP and HPMCE3 were used to prepare polymeric ASD of lapatinib at a drug-topolymer ratio of 1:3 following a procedure previously described by de Araujo et al58. The drug and
polymer were solubilized in a binary solvent system, consisting of dichloromethane and methanol
at 70:30 v/v, prior to the spray drying process. The solution had a total solid concentration of 2%
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w/v. The Buchi B-290 spray dryer (Buchi, New Castle, DE) was operated at an inlet temperature
of 75 °C and an outlet temperature of 45 °C. The aspirator flow was set at 400 (arbitrary units) and
the pump rate was calibrated at 5 mL/min. The spray dried materials were collected and stored at
ambient temperature in a desiccator to be used as the intragranular component.
4.2.3 PXRD and Solubility Testing
ASD formation of lapatinib was confirmed using power x-ray diffraction (PXRD) analysis
(Rigaku, Inc. The Woodlands, TX, USA). The diffractometer was equipped with a Cu-Kα radiation
and operated at 40 kV and 40 mA. A scan from 5˚ to 40° 2θ was used at a speed of 2° per minute
with 0.04° step size. The Solapp of lapatinib ASD was measured by adding an excess amount of
solid material in phosphate buffered saline (PBS) at pH 7.4. The mixture was stirred and incubated
at 37 °C for 24 hours. The sample was centrifuged at 5,000×g for 5 minutes. The supernatant was
transferred and subjected to a second centrifugation at 15,000×g for 20 minutes. The final
supernatant was diluted and analyzed with high performance liquid chromatography (HPLC).
The concentration of lapatinib in the sample was determined using a calibration curve based on
the signal produced by the UV absorbance at 280 nm. A Zorbax XDB-C8 column (4.6 mm x 15
mm, 5 µm) was used as the stationary phase. The mobile phase composed of (A) aqueous solution
with 0.1% v/v triethylamine + 0.04% v/v acetic acid and (B) acetonitrile. The composition of B
started from 50% at 0 minute and increased over a linear gradient to 75% at 13 minutes. A flow
rate of 1.0 mL/min was maintained. The same method was used for all other HPLC analyses
performed in this study.
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4.2.4 Mini-tablet Manufacturing
The ASD (20%) was combined with other excipients, including Avicel® PH 200, CCS,
colloidal silicon dioxide and magnesium stearate, as shown in Table 4.1. ASD prepared via spray
drying was used as the intragranular material. The final blend (10 – 20 g in total weight) was
prepared by mixing ASD with extragranular excipients listed below prior to tablet compression.
API: active pharmaceutical ingredient.. The batch sizes ranged from 10 – 20 grams in weight. All
ingredients were blended using a vortex mixer for 10 minute, except for magnesium stearate (1%)
and a small portion of Avicel® PH 200 (24%), which were mixed separately for 1 minute before
combining into the final blend. The blending process was continued for an additional 10 minutes
after magnesium stearate was added. The effect of CCS as the disintegrant on dissolution profiles
at 2%, 4% and 6% were assessed for mini-tablets containing lapatinib ASD with HPMCP and
HPMCE3 (Table 4.2. The changes in the composition of mini-tablets formulations include (1)
amount of disintegrant added at a continuous level from 2% to 6% and (2) the type of polymeric
excipient used to prepare lapatinib ASD as the intragranular material.). The amount of diluent,
Avicel® PH 200, was adjusted to accommodate the changes in the composition of the CCS.
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Table 4.1. ASD prepared via spray drying was used as the intragranular material. The final blend
(10 – 20 g in total weight) was prepared by mixing ASD with extragranular excipients listed
below prior to tablet compression. API: active pharmaceutical ingredient.
Ingredient

Purpose

Percentage

-------------------------------------------Intragranular ASD------------------------------------------Lapatinib
HPMCP/ HPMCE3

API

5

Polymer

15

----------------------------------------Extragranular Excipients---------------------------------------Diluent

71 – 75%

Croscarmellose sodium

Disintegrant

2 – 4%

Colloidal silicon dioxide

Glidant

2

Lubricant

1

Avicel® PH 200

Magnesium stearate

Table 4.2. The changes in the composition of mini-tablets formulations include (1) amount of
disintegrant added at a continuous level from 2% to 6% and (2) the type of polymeric excipient
used to prepare lapatinib ASD as the intragranular material.
Factor

Level (-)

Level (0)

Level (+)

Continuous--------------------

Min

Mid

Max

Amount of disintegrant

2

4

6

Categorical--------------------

Type I

Type II

-

ASD polymeric excipient

HMPCP

HPMCE3

-

The final blend was used to make mini-tablets via direct compression using Piccola PLC B rotary tablet press (Riva, Aldershot, UK). A 2-mm, standard cup tablet punch set (Natoli, St
Charles, MO, USA) was installed on the tablet press. The final blend was loaded on the gravity
feeder. The mini-tablets were compressed at a target weight of 7.0 ± 0.5 mg and a target
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compression force of 0.5 ± 0.2 kN during production runs. The tooling used in this study had a
maximum tip force limit of 1.1 kN, which was determined by the manufacturer.
4.2.5 Tensile Strength and Friability Testing
The individual weights of 10 mini-tablets were obtained for each formulation. The diameter
and height were measured using a Vernier caliper (Tresna, Essen, Germany). The breaking force
of the mini-tablet was obtained using Vanderkamp® VK 200 tablet hardness tester. The tensile
strength was calculated for each tablet using the equation below where F is the breaking force, D
is the tablet diameter and H is the tablet thickness.
𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑆𝑡𝑟𝑒𝑛𝑔𝑡ℎ =

2𝐹
𝜋𝐷𝐻

A set of 20 mini-tablets were sampled and the total weight were obtained. 3-mm glass
beads were added at a total weight of 6 g to aid the friability testing. The mini-tablets and glass
beads were placed in the drum of VanKel friabilator, which was set to run for 100 revolutions. The
mini-tablets were separated from the glass beads and dedusted. The final weight of the mini-tablets
was obtained, and the percent friability was calculated based on the ratio of the weight loss after
being subjected to the test over the initial weight.
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐹𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =

𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑊𝑒𝑖𝑔ℎ𝑡 − 𝐹𝑖𝑛𝑎𝑙 𝑊𝑒𝑖𝑔ℎ𝑡
× 100
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑊𝑒𝑖𝑔ℎ𝑡

4.2.6 Assay and Content Uniformity Testing
A total of 10 mini-tablets from each formulation with HPMCP and HPMCE3 were tested
for the individual drug contents. A mini-tablet was placed in a scintillation vial containing 2 mL
of distilled water and allowed to disintegrate over a 5-minute period. 18 mL of methanol was added
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to the vial and vortexed for 5 minutes followed by homogenization for another 5 minutes. The
mixture was centrifuged at 15,000×g for 5 minutes and the supernatant was analyzed using HPLC.
Content uniformity testing was performed based on USP <905> using the individual drug content
of the mini-tablets analyzed with the assay method described above. The acceptance value (AV)
was calculated using the equation below, where M is the reference value, k is the acceptability
constant, 𝑋̅ is the mean value for individual content and s is the standard deviation.
𝐴𝑉 = |𝑀 − 𝑋̅| + 𝑘𝑠
4.2.7 Dissolution Testing
The drug release profile of 10-tablet samples was tested using Erweka DT 600 dissolution
tester (ERWEKA GmbH, Heusenstamm, Germany) with USP apparatus II at a paddle speed of
100 rpm. PBS with 0.2% sodium lauryl sulfate (SLS) at pH 7.4 and simulated gastric fluid (SGF)
without pepsin at pH 1.2 were used as the dissolution media and maintained at 37 °C throughout
the test. SLS was added to facilitate the wetting process. SGF was prepared by adding 0.2% w/v
of sodium chloride in 0.1N of hydrochloric acid solution. The amount of drug released during
dissolution test was analyzed at 5, 15, 30, 45, 60, 75, 105 and 120 minutes using HPLC. All
samples were tested in triplicates under sink condition.
The disintegration time was recorded at the beginning of the dissolution test after minitablets completely disintegrated to form white granules based on visual observation. It should be
noted that the disintegration times were not measured according to the USP <701> in which a
basket-rack assembly is used as an apparatus for disintegration test. The mini-tablets are very small
making it difficult to visually observe the disintegration process using the basket-rack assembly
setup.
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4.2.8 Pharmacokinetic Study
The study was carried out under the supervision of a staff veterinarian of Purdue’s Lab
Animal Program using the protocol (1112000407E001) approved by the Purdue Animal Care and
Use Committee. Juvenile landrace pigs were obtained 7 days prior to the study, during which they
were socialized. A surgical procedure was performed 24 hours before the study to insert a jugular
catheter, externalized in the dorsal scapular region as described previously. After the surgery, the
pigs were placed in a movement responsive cage system (PigTurn®, Bioanalytical System Inc.,
West Lafayette, IN, USA) to prevent entanglement of the catheter lines. When the animal rotates
more than 270°, the system receives a signal transferred through the catheter to response with a
movement in the opposite direction. This facilitates automated blood sampling while minimizing
the stress experienced by the animal and the researcher during PK studies.
The study was conducted in two separate rounds with the same pigs and at two different
body weights. In the first round, the juvenile pigs at 10 kg body weight (approximately 1-month
old) were given 40 units of mini-tablets dispensed in a size-2 capsule shell and administered using
a pill syringe. Mini-tablets formulated with lapatinib ASD using HPMCP and HPMCE3 were
tested in the porcine models (n = 3 to 4) at 1.4 mg/kg. The pigs were housed in the facility until
they reached 20 kg in weight for the second round of the study. A fixed-dose of 1.4 mg/kg was
maintained by dosing the 20 kg pigs with 80 units of mini-tablets dispensed in a size-0 capsule.
Blood samples of 1 mL were collected at 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 20 and 24 hours after dosing
at both weights and transferred into vials containing tri-potassium ethylenediaminetetraacetic acid
(K3EDTA). The vials were centrifuged at 4 °C and processed to extract plasma, which was then
stored at -80 °C before analysis using liquid chromatography-tandem mass spectroscopy
(LC/MS/MS).
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4.2.9 Lapatinib Bioanalysis
Lapatinib was extracted from plasma in a similar manner to Haouala et al59. Plasma was
stored at -80 °C prior to extraction. Frozen plasma was thawed and transferred at an amount of
0.1 mL for extraction.

13

C2,

15

N1-lapatinib was used as the internal standard with 20 ng being

added to each aliquot immediately prior to extraction. Extraction and protein precipitation was
done by the addition of 0.5 mL of acetonitrile. Each sample was vortexed for 5 minutes, then
centrifuged at 13,000 rpm for 10 minutes. Supernatant was transferred to an autosampler vial and
analyzed using LC/MS/MS.
An Agilent 1200 Rapid Resolution liquid chromatography (LC) system coupled to an
Agilent 6460 series QQQ mass spectrometer (MS) was used to analyze lapatinib/ 13C2,

15

N1-

lapatinib in each sample. An Agilent PFP 2.1 mm x 100 mm, 3 µm column was used for LC
separation (Agilent Technologies, Santa Clara, CA). The buffers were (A) water + 0.1 % formic
acid and (B) acetonitrile + 0.1% formic acid. The linear LC gradient was as follows: time 0
minutes, 5 % B; time 1 minute, 5 % B; time 10 minutes, 95 % B; time 11 minutes, 95 % B; time
12 minutes, 5 % B; time 15 minutes, 5 % B. Multiple reaction monitoring was used for MS
analysis. The lapatinib data were acquired in positive electrospray ionization (ESI) mode by
monitoring the following transitions: 581.1 to 458 (25V), 379.1 (40V), 365.1 (45V), and 350
(45V). The 13C2, 15N1-lapatinib data were also acquired in ESI mode by monitoring the following
transitions: 584.1 to 458 (25V), 381.1 (40V), 366.1 (45V), and 350 (45V). The jet stream ESI
interface had a gas temperature of 330°C, gas flow rate of 8 L/min, nebulizer pressure of 40 psi,
sheath gas temperature of 250°C, sheath gas flow rate of 7 L/min, capillary voltage of 4000 V, and
nozzle voltage of 1000 V.
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All data were analyzed using Agilent MassHunter Quantitative analysis software (version
6.0). The lapatinib peaks eluted at 7.9 minutes. The 581.1 to 365.1/584.1 to 366.1 transition was
used as the quantifying ion for the analysis. The calibration curve range was 10,000-1 ng/mL in
plasma. The correlation coefficient (r2) was >0.999 and all data were normalized to the 13C2, 15N1lapatinib internal standard peak.
4.2.10 Pharmacokinetic Analysis
Data fitting and parameter estimation of lapatinib concentration-time data were performed
in SimBiology® from The MathWorks, Inc. (Natick, MA, USA). The PK parameters investigated
include maximum plasma concentration (Cmax), time to reach the maximum concentration (Tmax),
area under the concentration-time curve (AUC), elimination half-life (T1/2, clearance (CL) and
volume of distribution (Vd). A one-compartment model with first-order elimination was used to
simulate the data.
4.2.11 Statistical Analysis
Statistical analysis was conducted using one-way ANOVA for all pair-wise comparisons with
Scheffe’s method testing on SAS (Cary, NC, USA). A p-value <0.05 was considered statistically
significant.

4.3

Results and Discussion

4.3.1 Mini-Tablet Manufacturing
Lapatinib was used as the active pharmaceutical ingredient (API) in this study to create a
mini-tablet formulation platform for expedited preclinical and clinical studies for pediatric drug
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assessment. 4-anilinoquinazoline derivatives such as lapatinib, gefitinib and erlotinib have been
investigated for their anticancer efficacy in pediatric clinical studies60–64. The intrinsic solubility
of lapatinib in its crystalline form was 0.1 µg/mL in PBS measured at pH 7.4 and 37 °C. The
intermolecular interaction of ASD can stabilize the drug in its amorphous form, providing an
increased Solapp, while inhibiting crystallization. According to the result from a stress test,
conducted by de Araujo and coworkers, crystallization was detected in the ASD prepared using
1:3 drug-to-polymer ratio with HPMCE3 after 30 days while the sample with HPMCP still
remained amorphous58. When HPMCP was added at 1:1 ratio of drug and polymer, however, the
sample began to crystallize after only 7 days, suggesting that superior physical stability can be
obtained when the polymer is added at 75% in the ASD.
In this study, the formation of lapatinib ASD was confirmed using PXRD, which showed
that the spray dried samples did not exhibit Bragg peaks associated with the crystalline form of the
drug (Figure 4.1). Lapatinib-HPMCP provided a highly significant increase in Solapp based on the
formation of a strong intermolecular interaction between the amine group and the phthalate group
on the polymer. This acid-base interaction is absent in lapatinib-HPMCE3, but hydrogen bonding
may play a role in the stabilization of the amorphous drug in this ASD system. This type of
interaction was also demonstrated using other drugs with a basic group and acidic polymers such
as HPMCAS, polyacrylic acid and Eudragit® L55,65,66.
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Figure 4.1. PXRD pattern of crystalline lapatinib and amorphous dispersions prepared using
spray dryer with HPMCP and HPMCE3 as the polymeric matrices.

The ASD of lapatinib containing HPMCP and HPMCE3 polymer were used in the minitablet formulation with other excipients as extragranular materials. All the ingredients were
combined to obtain the final blend. The mini-tablets were produced using a rotary tablet press and
the compression force was recorded during the production as shown in Figure 4.2. A consistent
tablet compression force was maintained at 0.5 ± 0.2 kN throughout the production time. The
physical properties of the mini-tablets are presented and discussed in the following sections.
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Figure 4.2. The main compression force was maintained at a 0.5 ± 0.2 kN during production for
mini-tablets with a target weight of 7.0 ± 0.7 mg and tensile strength of 3.8 ± 0.4 N/mm2.
4.3.2 Characterization of Mini-Tablets
Physical properties of mini-tablet are listed in Table 4.3. The physical characteristic of mini-tablets
from six batches manufactured using blending and direct compression with the same setup. The
weight, diameter, thickness, breaking force and tensile strength values are reported as mean ± SD
with n = 10 samples selected from each batch. The percent friability was obtained using a sample
of 20 mini-tablets with 6 grams of glass beads added to aid in the testing process. for six batches
separately prepared using the same setup in blending and compression. The batches were made
using different formulations with the two amorphous dispersions combined with varying amounts
of CCS. Reported in Table 4.3. The physical characteristic of mini-tablets from six batches
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manufactured using blending and direct compression with the same setup. The weight, diameter,
thickness, breaking force and tensile strength values are reported as mean ± SD with n = 10 samples
selected from each batch. The percent friability was obtained using a sample of 20 mini-tablets
with 6 grams of glass beads added to aid in the testing process. are the mean values and standard
deviations for weight, diameter, thickness, breaking force and tensile strength of 10 mini-tablets
from each batch. There were no statistically significant differences observed in the weight,
diameter, thickness, breaking force, tensile strength and percent friability for mini-tablets sampled
from the six separate runs.
Table 4.3. The physical characteristic of mini-tablets from six batches manufactured using
blending and direct compression with the same setup. The weight, diameter, thickness, breaking
force and tensile strength values are reported as mean ± SD with n = 10 samples selected from
each batch. The percent friability was obtained using a sample of 20 mini-tablets with 6 grams of
glass beads added to aid in the testing process.
Weight

Diameter

Thickness

Breaking Force

Tensile Strength

Friability

(mg)

(mm)

(mm)

(N)

(N/mm2)

(%)

1

7.0 ± 0.1

1.99 ± 0.01

2.00 ± 0.02

24.6 ± 4.6

4.0 ± 0.8

0.001

2

6.9 ± 0.3

1.98 ± 0.01

2.01 ± 0.03

20.6 ± 4.5

3.3 ± 0.7

0.001

3

6.9 ± 0.2

1.98 ± 0.00

1.97 ± 0.04

22.1 ± 2.7

3.6 ± 0.5

0.001

4

6.7 ± 0.1

1.98 ± 0.00

1.90 ± 0.04

23.3 ± 2.6

4.0 ± 0.5

0.001

5

6.7 ± 0.1

1.97 ± 0.00

1.95 ± 0.03

22.1 ± 1.4

3.7 ± 0.3

0.010

6

6.7 ± 0.1

1.98 ± 0.01

1.90 ± 0.03

23.3 ± 2.6

4.0 ± 0.5

0.001

Batch

The tablet weights were maintained within the target value of 7.0 ± 0.7 mg (Table 4.3. The
physical characteristic of mini-tablets from six batches manufactured using blending and direct
compression with the same setup. The weight, diameter, thickness, breaking force and tensile
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strength values are reported as mean ± SD with n = 10 samples selected from each batch. The
percent friability was obtained using a sample of 20 mini-tablets with 6 grams of glass beads added
to aid in the testing process.). The diameter and thickness of the mini-tablets were within 10% of
the targeted measurement of 2.00 mm. The mini-tablets had a diameter-to-thickness ratio close to
1 and are less prone to breaking during storage and transportation. The mean breaking force ranged
from 20 to 25 N, and the standard deviations were less than 25% of the mean values for each batch
of mini-tablets. The tensile strength, calculated based on the tablet dimensions and breaking force,
fell within the target range of 3.8 ± 0.4 N/mm2. The percent friability ranged between 0.001% and
0.01% for all the batches tested. The consistency in physical properties of mini-tablets revealed
that the manufacturing method used in this study is appropriate for assessing the changes in
formulation factors utilized in this study.
4.3.3 Assay and Content Uniformity
The two lapatinib ASDs consisted of 75% polymer and were added in the powder blend at
20%. Each mini-tablet was 7.0 mg in weight and containing 0.35 mg or 5% of API. The mean drug
content was 90 ± 2% and 107 ± 4% for formulation containing lapatinib-HPMCP and lapatinibHPMCE3, respectively (Table 4.4. Individual drug content of mini-tablets prepared using
amorphous dispersions of lapatinib with different polymeric excipients. The target drug content is
100% or 0.350 mg calculated based the individual weight of mini-tablets and drug assay analyzed
using HPLC. The values are reported as mean ± SD with n = 10 samples.). This suggests that the
API is distributed fairly evenly in the final blend and the rotary tablet press can be used for minitablet manufacturing. The acceptance value of mini-tablets prepared from using the two
amorphous dispersions were below 15.0 maximum limit in the USP <905>. The rotary tablet press
consists of multiple press stations, and it can provide increased productivity compared to a single-
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station tablet press and hydraulic hand press. It also provides independent weight and hardness
control.
Table 4.4. Individual drug content of mini-tablets prepared using amorphous dispersions of
lapatinib with different polymeric excipients. The target drug content is 100% or 0.350 mg
calculated based the individual weight of mini-tablets and drug assay analyzed using HPLC. The
values are reported as mean ± SD with n = 10 samples.
Individual Drug Content

Acceptance Value

(Target: 100% or 0.350 mg)

(L1 = 15.0 max. allowed)

Lapatinib-HPMCP

90 ± 2% (0.315 ± 0.007 mg)

14.7

Lapatinib HPMCE3

107 ± 4% (0.374 ± 0.014 mg)

15.0

Formulation

The content uniformity of the drug is very important for mini-tablets manufacturing
because they are small and often dispensed as multiparticulate dosage forms in capsule, sachet and
stick pack. A small deviation from the target value can result in a large percentage change in drug
content indicated on the label claim. The mean value drug content for mini-tablets containing
lapatinib-HPMCP amorphous dispersion was 0.315 mg, which is 10% lower than the targeted drug
content of 0.350 mg. When lapatinib-was used as the ASD in the mini-tablet formulation, the
individual drug content was slightly over 100%.
The individual drug contents of mini-tablets formulated using lapatinib-HPMCP were
consistently lower than lapatinib-HPMCE3. The lack of a suitable solvent for drug extraction has
been hypothesized as the reason for the difference between these the formulations. HPMCP is
soluble in a limited number of organic solvents including dichloromethane and methanol, while
lapatinib is only slightly soluble in methanol. Dichloromethane is a volatile liquid that is
immiscible with water, so it cannot be used for this purpose. Both the polymeric excipient and
lapatinib must be soluble in the solvent to efficiently extract the drug in the assay testing. In

112
addition, lapatinib-HPMCP has a stronger intermolecular interaction between the drug and the
polymer, facilitated by acid-base formation, compared to hydrogen bonding interaction in
lapatinib-HPMCE3. Based on these differences, the potential differences in content uniformity
may be at least explained in part.
4.3.4 Dissolution Profiles
The drug release profiles of mini-tablets formulated using CCS as the disintegrant at 2%,
4% and 6% are shown below for lapatinib-HPMCP (Figure 4.3) and lapatinib-HPMCE3 (Figure
4.5). A drug release of over 65% was obtained for lapatinib-HPMCP regardless of the percent
disintegrant added. There was a significant difference in the drug release for the formulation
containing 2% CCS compared to 4% and 6% at the 5 minutes time point (Figure 4.3b). The
differences became less significant at 15 and 30 minutes. The drug release for 4% and 6% CCS
were not significantly different at 5 and 15 minutes. At 30 minutes, the drug release for 4% CCS
was statistically lower than 6% CCS.
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Figure 4.3. Drug release for mini-tablets formulated using lapatinib-HPMCP as the amorphous
dispersion in PBS + 0.2% SLS at pH 7.4 and 37 °C (a) over a 2-hour period and (b) after 5, 15
and 30 minutes. Significant changes are denoted with * (p < 0.05) or ** (p < 0.005).
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In another experiment, the dissolution test using the same medium was run for 2-hours
before a final sampling to analyze the drug release, the differences were not found to be statistically
significant for formulations containing 2%, 4% and 6% CSS. This confirms that the % CCS added
only affected the initial drug release during the initial time points of 5 to 30 minutes. Since there
was no sample taken before the 120 minutes time point, this test provided more accurate data on
the percent of drug release from the mini-tablets over an extended period. In the initial dissolution
test, multiple samplings were performed throughout the 120-minutes period, there were some
undissolved solids in the samples that were removed by centrifugation. The solid content that
presented during the disintegration process can result in a small difference in the amount of
cumulative drug release after it was removed. At 2% CCS, the mini-tablets took 24 minutes to
completely disintegrate while the disintegration times were between 5 – 6 minutes for 4% and 6%
CCS. In this study, the disintegration time was recorded based on the amount of time it took for
the mini-tablets to completely disintegrate and form white granules at the bottom of dissolution
kettle.
A similar trend was also seen for mini-tablets containing lapatinib-HPMCE3. The drug
release of the formulation containing 2% CCS was significantly lower than the 4% and 6% CCS
formulations at 5 minutes, while there was no difference between 4% and 6% CSS (Figure 4.5).
The drug release levels were not significantly different between all three formulations at 15 and
30 minutes. After 45 minutes, 75% of drug released from the mini-tablets for all formulations and
up to 84 ± 0.7% for formulation containing 6% CCS. When the drug release was analyzed only
after 120 minutes, the samples did not show a significant difference. The disintegration times for
2% CCS formulation was 18 minutes, while mini-tablets with 4% and 6% CSS added took 12 –
13 minutes.
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Figure 4.4. Disintegration times recorded at the beginning of the dissolution test (a) and percent
drug release analyzed with a sample taken after 120 minutes (b) for mini-tablet prepared using
lapatinib-HPMCP amorphous dispersion with 2%, 4% and 6% of croscarmellose added as a
disintegrant. Significant changes are denoted with * (p < 0.05) or ** (p < 0.005).

116

a
100

Drug release (%)

80

60
2%
4%
6%

40

20

0
0

20

40

60

80

100

120

Time (min)

b
100

Drug release (%)

80

**

60

NS

*
40

20

0
2% 4% 6%
05 minutes

2% 4% 6%
15 minutes

2% 4% 6%
30 minutes

Figure 4.5. Drug release for mini-tablets formulated using lapatinib-HPMCE3 as the amorphous
dispersion in PBS + 0.2% SLS at pH 7.4 and 37 °C (a) over a 2-hour period and (b) after 5, 15
and 30 minutes. Significant changes are denoted with * (p < 0.05) or ** (p < 0.005).
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Figure 4.6. Disintegration times recorded at the beginning of the dissolution test (a) and percent
drug release analyzed with a sample taken after 120 minutes (b) for mini-tablet prepared using
lapatinib-HPMCE3 amorphous dispersion with 2%, 4% and 6% of croscarmellose added as a
disintegrant. Significant changes are denoted with * (p < 0.05) or ** (p < 0.005).

HPMCP is commonly used as an enteric coating polymer for controlled release formulation.
It can also function as a protective coating for acid-labile drugs from potential degradation in the
gastric environment where the pH level is approximate 1.2. When the simulated gastric fluid
without pepsin was used as the dissolution medium, the mean drug release was less than 25% at
the 120 minutes time point. At a lower pH of 1.2 (SGF), the cumulative drug release was
significantly lower comparing to PBS + 0.2% SLS at pH of 7.4. HPMCE3 is stable in solution at
pH of 3 to 11. A pH level less than 3 may interfere with the ability of HPMCE3 to stabilize the
drug in solution leading to potential crystallization during the dissolution test. The drug release
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from mini-tablet containing lapatinib-HPMCE3 was 38 ± 1% which was significantly higher than
the values obtained from the formulation containing lapatinib-HPMCP with the same level of
disintegrant (4%) added.
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Figure 4.7. Effects of pH level at 1.2 and 7.4 on the dissolution profile of mini-tablets prepared
using lapatinib-HPMCP and lapatinib-HPMCE3 with the same level of croscarmellose sodium
(4%) added.

A high drug release was also observed for lapatinib-HPMCE3 compared to lapatinibHMPCP when the dissolution test was performed at pH 7.4. The amount of free drug available in
solution is dictated by the release of drug from the polymer. A stronger intermolecular interaction
in the amorphous dispersion of lapatinib with HPMCP may affect the release of the drug from
polymer and reduce the amount of free drug detected. An inverse relationship between the increase
in apparent solubility and the reduction in the amount of free drug in solution was reported for
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different intermolecular interactions between the drug and various polymers used as an excipient
in the ASD systems. The increase in apparent solubility of the drug in ASD systems was
accompanied by a decrease in the permeability coefficient obtained using Caco-2 monolayers for
three different drugs, namely niclosamide, celecoxib and resveratrol. The details of this study can
be found in Chapter 2.
4.3.5 Pharmacokinetic of Lapatinib in Juvenile Porcine Models
Juvenile pigs at 10 kg were dosed with 40 mini-tablets, which was equivalent to 1.4 mg/kg
of lapatinib. Formulation of lapatinib-HPMCP and lapatinib-HPMCE3 were used in this study. A
washout period of 24 hours was allowed after the last blood sample was taken and before the
administration of the next dose. Lapatinib-HPMCP formulation resulted in Cmax of 8.6 ng/mL and
Tmax of 2.5 hours. A significantly higher Cmax value at 14.0 ng/mL was obtained with mini-tablets
containing lapatinib-HPMCE3 amorphous dispersion (p-value <0.05). The weight-normalized CL
was also higher with a p-value <0.05 when the lapatinib-HPMCE3 was used. Other parameters
including Tmax, AUC, and Vd were similar between the two formulations. The inter-animal
coefficient of variance (CV) was greater for the AUC value of lapatinib-HPMCE3 based on the
mean and standard deviation of 147 ± 94 ng.h/mL. There was an apparent large variation between
the subjects in the study with lapatinib-HPMCE3 samples, which was not expected.
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Table 4.5. The PK parameters of lapatinib obtained using juvenile porcine models at two
different body weights (10 kg and 20 kg) for two different formulations with (A) lapatinibHPMCP and (B) lapatinib-HPMCE3. The statistical significance based on pair-wise comparison
of all the parameters are presented below with * (p < 0.05).
Formulation

Parameter

Body Weight
10 kg
M ± SD

Statistical Significance

20 kg
CV

M ± SD

CV

A10

A10

A20

A20

B10

B20

Lapatinib

Cmax (ng/mL)

8.6 ± 2.2

26

9.1 ± 3.0

33

NS

*

NS

HPMCP

Tmax (h)

2.5 ± 0.9

36

2.0 ± 0.0

0

NS

NS

NS

(A)

AUC (ng.h/mL)

76 ± 12

16

90 ± 26

29

NS

NS

NS

T1/2 (h)

2.0 ± 0.3

15

1.4 ± 0.6

43

NS

NS

NS

CL (L/h/kg)

20 ± 6

30

20 ± 9

45

NS

*

NS

Vd (L/kg)

57 ± 22

39

44 ± 27

61

NS

NS

NS

Lapatinib

Cmax (ng/mL)

14.0 ± 3.3

24

16.4 ± 8.8

54

NS

HPMCP

Tmax (h)

3.5 ± 1.7

49

2.3 ± 1.2

52

NS

(B)

AUC (ng.h/mL)

147 ± 94

64

87 ± 24

28

NS

T1/2 (h)

3.3 ± 2.0

61

2.0 ± 1.0

50

NS

CL (L/h/kg)

10 ± 4

40

18 ± 8

44

NS

Vd (L/kg)

40 ± 7

18

55 ± 44

80

NS
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Figure 4.8. Plasma concentration versus time profile of lapatinib formulated as amorphous solid
dispersion with HPMCP (Formulation A) as the polymeric excipient in (a) 10 kg pigs of n=4 and
(b) 20 kg pigs n=3.
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Figure 4.9. Plasma concentration versus time profile of lapatinib formulated as amorphous solid
dispersion with HPMCE3 (Formulation B) as the polymeric excipient in (a) 10 kg pigs of n=4
and (b) 20 kg pigs n=3.
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The second round of dosing was performed when the pigs reached 20 kg in body weight to
investigate the ontogeny effects on PK parameters of lapatinib. A pair-wise comparison between
the pigs at 10 kg and 20 kg showed that there no significant difference in all parameters based on
age/weight category. This was true for both mini-tablets prepared using amorphous dispersions
with HPMCP and HPMCE3. It should be noted that the dose level was kept at 1.4 mg/kg in both
rounds of the study, which was facilitated by the application of a flexible amount of mini-tablets.
At 20 kg body weight, there was no difference between the two formulations used with Cmax values
ranged from 9.1 and 16.4. The Tmax, AUC, T1/2, CL and Vd were similar. The CV was below 65%
for all the parameters except Vd, which has a CV of 88% for the lapatinib-HPMCE3 formulation
at 20 kg.
Table 4.6. Comparative analysis of lapatinib PK parameters obtained from juvenile porcine
models with human pediatric data from Phase I clinical trial conducted by Fouladi et al.60 Note
(8): converted from 900 mg/m2 divided by Km=25.
Dose (mg/kg)

Porcine

1.4

n

4

Characteristics:

Normalized

Tmax

Normalized

Age

Cmax

Disease State

(ng/mL)

(h)

(ng/mL x h)

1 month

4 – 14

2.0 – 6.0

41 – 220

2 – 20

2.0 – 4.0

19 – 86

42 – 208

3.2 – 8.1

230 – 2,066

AUC

Healthy
3

2 months
Healthy

Human

36.0*

5

1 – 21 years
CNS tumors
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A PK study of lapatinib in pediatric patients (age 1 to 21 years old) with refractory CNS
malignancies was conducted by Fouladi et al60. The dose-normalized Cmax, and AUC from the
juvenile porcine model did not fall in the range observed from pediatric human provided after dose
normalization. According to the pediatric clinical trial, Cmax ranged from 42 – 208 which is
approximately 10 fold higher than the values obtained from 10kg and 20 kg pigs. Similarly, the
normalized AUC values in pediatric humans are also about 10 fold higher. There is an overlap in
the Tmax values between juvenile pigs and pediatric subjects ranged at 2.0 to 6.0 and 3.2 to 8.1,
respectively. The clinical study also determined a recommended dose of 900 mg/m2 for phase II
trial. This dose is similar with therapeutic level in adult (880 mg/m2). The PK parameters of
lapatinib in adult patients with solid malignancies, the AUC value was reported to 12.2 ± 1.94
µg/mL (dose-normalized: 338 ± 54 ng) when the same dose level of 900 mg/m2 was used67. The
similarities can suggest that a linear dosing can be used for lapatinib in adult and children. In our
study, the same level of Tmax, AUC and T1/2 was also obtained when the dose is maintained at 1.4
mg/kg for both age groups in juvenile pigs.
It should be noted that the dosing level used in the clinical trial was in body surface area
scale (mg/m2). For the PK comparison, mg/m2 was converted to mg/kg by multiplying constant,
Km equal to 25. This reference value is provided in the FDA guidance for estimating dose of initial
clinical trials68. The guidance also suggests a human equivalent dose (HED) factor of 1.4 and 1.1
for micro-pigs and mini-pigs, respectively. However, these factors are only available for
conversion between animals and adult humans. It is also pointed out in the guidance that the Km
constant of 25 is used for a child (20 kg) is provided as a reference for healthy children. The
participants enrolled in pediatric clinical trials are often non-healthy, which can affect this matrix.
Due to the lack of a better conversion system, this Km is used for the comparative analysis in this
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study. Another factor to consider is the difference in the amorphous form of the drug used in this
study versus the lapatinib ditosylate formulation used in the clinical trial. The comparative analysis
between the juvenile animals and humans are limited by the lack of information on pediatric
patients. The differences in dosing scale, regimen (once versus twice daily) and current versus
investigational formulation can affect the comparison. Another shortcoming is the lack of research
work on the study of different subgroup of pediatric population. The insufficient progress in
pediatric drug development, however, is still creating a large backlog of clinical and preclinical
studies to be conducted.

4.4

Conclusions
Mini-tablets, 2 mm in diameter, were prepared using the lapatinib ASD with two different

polymeric excipients (i.e. HPMCP and HPMCE3). The physical properties of mini-tablets (weight,
dimension, tensile strength, percent friability) were similar for all batches produced in this study.
The manufacturing procedure used in this study is applicable for all formulation factor changes as
demonstrated. The dissolution testing revealed that the amount of disintegrant added (i.e. CCS)
affected the drug release profile between the 5 and 30 minutes time points. There was no significant
difference in the cumulative amount of drug release after the 30 minutes time point. The minitablets provided flexibility in the animal study as the amount of drug given was adjusted based on
body weight to maintain the same dose level for both rounds. The Tmax obtained from juvenile pigs
overlapped with the values provided in a pediatric clinical trial, while Cmax and AUC are 10-fold
lower. Differences in the Cmax and the AUC between the porcine model and children may be due
to several factors including the dose scaling methods, the physical properties of state, and the
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broader age range in the pediatric trial. Since the mini-tabs are a flexible dosing formulation, the
number administered could be adjusted to match the Cmax and AUC desired in pediatric patients.
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CONCLUDING REMARKS

An optimal balance of stability, solubility and drug permeation is required in formulation
design to obtain a safe and efficacious drug product. The interplay between apparent drug
solubility and apparent permeability coefficient can directly affect flux value, which is dependent
on the amount of free drug available for absorption. The intermolecular interaction(s) between the
drug molecule and the polymeric excipient in the amorphous dispersion can be used to achieve a
formulation with increased solubility and drug absorption. Some of the physiologically relevant
factors that should be considered when performing preclinical screening of solubility enhancing
formulations are discussed in this dissertation.
In Chapter 2, we demonstrated that the increase in apparent solubility of drug was
accompanied by the decrease in apparent drug permeability as found in all three drug compounds
used in the study. A similar effect was observed for drug dissolution study conducted in Chapter
4. The addition of HPMCP as the polymeric excipient provide a stronger interaction with the drug
molecules due to an acid-base reaction formed between the secondary amine on lapatinib and
acidic functional group on the polymer. The mini-tablet containing lapatinib-HPMCP solid
dispersion, however, resulted in a significantly lower drug release compared to the mini-tablets
containing lapatinib-HPMCE3 in which the acid-base interaction is not present.

Further

investigation on the effect of intermolecular interaction between the drug and the polymeric carrier
can provide more insights on the understanding of the interplay between different properties in
drug formulation and how they can be optimized to obtain a more effective drug product. Some of
the research studies include drug release mechanism in dialysis system and other transport assays.
A platform created for expedited preclinical study of pediatric formulation using minitablets can provide solution to multiple issues commonly associated with pediatric drug
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development including (1) dysphagia or swallowing difficulty, (2) low water solubility and (3) the
potential application of juvenile porcine models for pediatric subgroup assessments. This platform
can also be used for other active ingredients in solid oral drug formulation. Gefitinib is another
tyrosine kinase inhibitor that is currently being investigated for pediatric application. The future
direction for this project should focus on improving physical characteristic of amorphous
dispersion such as flow properties in order to achieve higher drug loading in the dosage form.
Some features of the in vivo pharmacokinetic study can be improved by using a higher number of
animal subjects, which can help improve the variation in the data. Due to rapid growth in juvenile
pigs, the changes body weight must be taken into consideration during the duration of the study.
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